分类： EQS Newswire

EQS Newswire / 09/06/2026 / 16:00 UTC+8 (9 June 2026, Hong Kong) Waton Financial Limited Unveils MoTA: An AI-Native Investment Team Operating System and Agent Marketplace That Lets Anyone Build, Manage, and Command Their Own Professional Investment Research Team Waton Financial Limited today unveiled MoTA (Manager of Trading Agents), an AI-native investment team operating system and Agent marketplace that redefines what AI can do for investors. MoTA is not a stock-picking chatbot or a black-box trading bot. It is a platform designed to let users build, manage, and command their own team of specialized AI Agents across the full investment workflow — from portfolio definition to trade execution. The Problem Professional investment research has always required a team: factor researchers, fundamental analysts, technical analysts, risk managers, portfolio constructors, and trade execution officers. Each role demands specialized talent and expensive infrastructure. For individual investors and small teams, assembling such a capability has been cost-prohibitive — until now. The Solution MoTA transforms the user from a passive consumer of AI signals into an active leader of an AI-powered investment team. Its four integrated modules work together to deliver a seamless, end-to-end experience. First, Talents — the Agent Marketplace. Users browse, compare, and hire specialized AI Agents by role. Each Agent is purpose-built for a specific investment function — fundamental analysis, technical analysis, risk management, trade execution, and more. Agents can be swapped and composed as strategies evolve. Second, Team — composing your investment team. Users assemble multiple Agents into a structured team. Analysts feed research inputs, the Portfolio Manager evaluates and writes memos, the Risk Manager reviews exposure, and the Trader validates routing. The human user retains final sign-off authority at every stage. Third, Portfolio — the portfolio cockpit. A real-time overview of holdings, assets, P&L, risk, and exposure. Users see exactly what is moving across positions, where risk sits, and where returns originate — all in one unified view. Fourth, Decision — the Decision Center. Every Agent-generated suggestion surfaces in the Decision Center with full context: source Agent, signal, reasoning, and current status. Users can click into the full workflow or execution path, compare competing analyses, and manage an actionable queue of decisions. Every recommendation is structured, traceable, and auditable. These four modules connect in a continuous workflow: Portfolio to Decision to Team to Trade. Why MoTA Is Different Traditional AI investing tools offer a single AI chat box, scattered research answers, black-box signals, no role separation, and AI value that is hard to measure. Reviews are tied to AI silos. MoTA provides a multi-Agent investment team, a connected Portfolio-to-Trade workflow, an auditable Decision Center, dedicated Analyst and PM and Risk and Trader roles in coordination, unified metrics such as ROI and win rate and cost per run and override rate, and a unified path for portfolio, decisions, Agents, and trades. The Vision Behind MoTA Waton Financial Limited's mission with MoTA is clear: to make professional-grade multi-agent investing tools more accessible, more transparent, and more user-controlled. MoTA does not replace human judgment — it amplifies it. The platform frees users from the burden of being a full-stack investment expert and elevates them to a higher role: the builder, manager, and decision-maker of their own AI investment team. As AI moves from content generation into workflow execution, investing — inherently a multi-role, multi-step, multi-constraint process — is a natural fit for this transformation. MoTA is designed to bridge the gap between what AI can do and what the investment workflow actually needs. About MoTA MoTA (Manager of Trading Agents) is Waton Financial Limited's flagship AI-native investment team operating system and marketplace for specialized investing Agents. It enables users to create fully customizable investment teams, assign specialized AI Agents to each role, and receive structured, traceable, and auditable investment suggestions across the entire Portfolio-to-Trade workflow. About Waton Financial Limited Waton Financial Limited is a publicly listed financial services and technology company that designs, owns, and operates the MoTA platform. Waton is committed to building AI-native infrastructure for investment teams and making professional-grade multi-agent investing tools accessible to a broader audience. Welcome to MoTA. Welcome to the new era of investing.   Media Contact Email: ir@watonfinancial.com Website: https://wtf.us Explore MoTA: https://mota.ai   Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those expressed or implied. This is not investment advice. Past performance does not guarantee future results. 09/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News. The issuer is solely responsible for the content of this announcement. Media archive at www.todayir.com View original content: EQS News

EQS via SeaPRwire.com / 12/06/2026 / 15:02 UTC+8 Shanghai - 12 Jun 2026 - The clinical datasets presented at ASCO 2026 further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy. I. Trispecific Design Rationale and Differentiated Advantages 1. Greater Potential for Long-Term Survival Benefit vs. PD-1+VEGF Combinations, with Low CTLA-4-Related Toxicity and Favorable Tolerability CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate deeper and more durable anti-tumor immune responses. • Differentiated CTLA-4 Design: The CTLA-4 component is engineered to avoid excessive activation of peripheral CTLA-4 single-positive T cells, thereby reducing systemic immune toxicity. Combined with VEGF-mediated tumor enrichment, this design preserves the immune-stimulatory benefit of CTLA-4 blockade while substantially improving tolerability. Clinical data has demonstrated that CTLA-4-related toxicities with CS2009 are notably lower than that of conventional CTLA-4 antibody regimens, with immune-related adverse events (irAEs) approaching incidence typically seen with PD-1 monotherapy or PD-1-based bispecific antibodies. • Advantage of Continuous Dosing: Unlike conventional CTLA-4 antibodies, which are often limited to two or three doses due to tolerability concerns, CS2009 can be administered continuously, therefore fully leveraging the CTLA-4 mechanism—not only initiating and enhancing existing anti-tumor T-cell responses but also continuously priming new T-cell clones against newly released tumor antigens throughout treatment. This ongoing expansion of the anti-tumor T-cell repertoire, combined with CS2009’s favorable tolerability, is expected to drive more durable immune responses, prolong clinical benefit, and ultimately improve overall survival. • Pharmacodynamic Validation: Dose-dependent upregulation in ICOS, a recognized pharmacodynamic marker of CTLA-4 pathway activation and T-cell activation, were observed. The ICOS elevation suggests that CS2009 continuously promotes T-cell priming and clonal expansion, validating the biological activity of its CTLA-4 module and providing biological basis for long-term anti-tumor activity. Industry challenge: Historically, most anti-VEGF plus PD-(L)1 regimens have primarily improved progression-free survival (PFS), while overall survival (OS) benefits remains highly uncertain. By incorporating a CTLA-4 mechanism, CS2009 aims to break through this limitation. 2. Low VEGF-Related Toxicity Supporting More Adequate Treatment Exposure and Sustained Clinical Benefit Pharmacodynamic data demonstrated: • Circulating VEGF levels have declined continuously following dosing, and no clear rebound has been observed after up to 147 days of follow-up. This pattern differs from results reported with traditional anti-VEGF antibodies or PD-1/VEGF bispecifics, potentially due to CS2009’s enrichment in the tumor microenvironment and CTLA-4-mediated internalization and clearance of VEGF-antibody complexes. This may reduce reflux of VEGF and its antibody-bound complexes into the peripheral circulation, thereby lowering VEGF-related systemic toxicities such as hypertension and proteinuria. Clinical data demonstrated: • The incidence of Grade ≥3 VEGF-related treatment-related adverse events (TRAEs) is only 5.1%, notably lower than reported rates for certain VEGF-based bispecifics. Industry challenge: VEGF is both a critical efficacy driver and a major source of toxicity in combination therapies. Achieving an optimal balance between efficacy and tolerability, particularly in elderly and high-risk patients, remains a longstanding, unresolved challenge in the VEGF field. 3. Consistent Activity Observed Across Multiple “Cold” Tumors, Highlighting the Value of the CTLA-4 Module and the Trispecific Mechanism Promising anti-tumor activity has been observed in several traditionally immunotherapy-insensitive tumor types, including: Immunotherapy-resistant non-small cell lung cancer (NSCLC), pMMR/MSS metastatic colorectal cancer (mCRC), Soft tissue sarcoma (STS), Non-clear cell renal cell carcinoma (nccRCC). These findings suggest that the combined blockade of PD-1 and CTLA-4, together with VEGF modulation, may enhance T-cell priming, broaden T-cell clonal diversity, promote durable immune memory, and improve T-cell infiltration within the TME—extending immune responsiveness to tumors that were previously I/O-insensitive. The consistent efficacy signals across multiple cold tumors support the ability of CS2009’s PD-1, CTLA-4 and VEGF synergism to reshape the immunosuppressive TME, expand the I/O-benefiting population, and demonstrate the potential to transcend the efficacy boundaries of traditional PD-1 inhibitors and PD-1/VEGF bispecifics. Industry challenge: Effective immunotherapy options remain limited for cold tumors. PD-1 plus CTLA-4 blockade is still one of the most widely recognized strategies for enhancing immunotherapy responsiveness. 4. Consistent Benefit Observed Across Squamous and Non-Squamous NSCLC • Across multiple NSCLC treatment settings, comparable response rates were observed in both squamous and non-squamous patients. CS2009 is showing a trend of consistent benefit across histological subtypes, indicating that its mechanism may not depend on a particular pathologic type and may cover a broader population of NSCLC patients, enhancing the probability of success in future global registrational trials. Industry challenge: Notable differences in efficacy between squamous and non-squamous NSCLC often limit the label expansion and commercial potential of certain products. II. Favorable Safety Profile with Notably Lower VEGF-Related Toxicity Compared with Bispecifics Safety data from the ongoing Phase I study in a mixed tumor population (N=118): • Grade ≥3 TRAE incidence: 24.6%; • Grade ≥3 irAE incidence: 12.7%; • Grade ≥3 VEGF-related TRAE incidence: 5.1%. Focusing on the later-line NSCLC cohort (n=57): • Grade ≥3 TRAE rate: 19.3%; • Grade ≥3 irAE rate: 12.3%; • VEGF-related Grade ≥3 TRAE rate: 5.3%; • Consistent with the safety profile of the overall heavily pretreated mixed-tumor population. Overall: • CTLA-4-related toxicity appears very well controlled. • No new or unexpected safety signals have been identified. • The overall safety profile is comparable to that of PD-1/VEGF bispecific antibodies, while VEGF-related toxicity appears substantially lower. This safety profile provides an important foundation for long-term dosing and future global registrational development. III. Efficacy in “Cold” Tumors Demonstrates Differentiated Clinical Value CS2009 has demonstrated meaningful clinical activity across multiple “cold” tumors, highlighting the differentiated mechanism. 1. Monotherapy in Later-Line pMMR/MSS mCRC • All enrolled patients had heavily pretreated, refractory CRC, including cases with BRAF mutations and right-sided tumors. • CS2009 monotherapy achieved an ORR of 25% and a DCR of 87.5%. Given that ORR in later-line colorectal cancer are typically in the single digits, these results demonstrate clinically meaningful anti-tumor activity. More importantly, efficacy signals emerging in a typical cold-tumor population further supports the differentiated value of the CTLA-4 module. 2. Combination with XELOX in First-Line pMMR/MSS mCRC • The study did not select patients by tumor sidedness, molecular subtype, or liver metastasis; the enrolled population better reflects real-world clinical practice. • To date, all six patients have experienced tumor shrinkage, and three patients achieved a partial response (PR) at their first efficacy assessment. • ORR was 66.7%, and DCR was 100%. Although the sample size remains small, highly consistent early efficacy signals have already been observed, providing positive support for subsequent global registrational development. The Company plans to expand the cohort to approximately 40 patients to generate a more comprehensive proof-of-concept (POC) dataset for upcoming discussions with the global regulatory authorities including the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) on a Phase III global registrational clinical trial. 3. Other “Cold” Tumors • Monotherapy in Later-line Soft Tissue Sarcoma (STS): ORR 33.3%, DCR 66.7%; • Monotherapy in Later-line non-clear cell renal cell carcinoma (nccRCC): ORR 33.3%, DCR 100%;. • Durable responses have also been observed. Notably, the first patient enrolled in Phase I (an Australian female) has experienced sustained tumor shrinkage of more than 40% over 12 months. IV. NSCLC: Multi-Dimensional Data Support Global Registrational Development Dimension 1: Later-Line NSCLC Monotherapy (Pretreated with IO, Chemotherapy, ADCs, or Bispecifics) • Overall ORR in the 30 mg/kg cohort: 24% (squamous 25%, non-squamous 23.1%, consistent benefit); DCR 60%; • In second-line NSCLC (30 mg/kg, post IO + chemotherapy): ORR improved to 30.8%, DCR 84.6%. • In such post-PD-(L)1 patient populations, standard-of-care ORRs are generally low, thus CS2009 has demonstrated competitive single-agent activity. Additional observations include: • 6-month duration-of-response (DOR) rate exceeded 80% (i.e., more than 80% of responders remained in response at 6 months); • Depth of response has continued to deepen over time; • DOR data are still maturing. Dimension 2: Later-Line NSCLC in Combination with Docetaxel • All six evaluable patients experienced tumor shrinkage, resulting in an ORR of 66.7% and a DCR of 100%. Although the sample size is currently small, these results are already very competitive within this class of studies. The company plans to expand the cohort to approximately 20 patients to inform subsequent registrational decisions. Dimension 3: First-Line NSCLC Monotherapy (PD-L1 TPS ≥50%) • Among 16 patients, ORR was 81.3% and DCR was 100%; • Squamous ORR 87.5%, non-squamous ORR 75%, consistent benefit; • Earlier data (March 2026) showed 9 PRs out of 10 patients; among the 6 newly enrolled patients, 4 achieved a PR at their first tumor assessment, bringing the total number of PRs observed to 13; • No responding patients have experienced rapid disease progression, and patients have shown deepening responses over time. While cross-trial comparisons have limitations, CS2009’s single-agent ORR in first-line NSCLC (PD-L1 TPS ≥50%) has reached a best-in-class range among comparable studies globally, demonstrating highly competitive clinical potential. Note: Data in the PD-L1 1%–49% population continue to mature. Dimension 4: First-Line NSCLC in Combination with Chemotherapy (Squamous, PD-L1 Low or Negative) • Among 8 squamous patients enrolled to date, 7 patients have PD-L1 ≤1% (low/negative), and 1 patient has PD-L1 ≤5% (low expression); median age is 70 years; • ORR was 75% and DCR was 100%; among PD-L1-negative patients, ORR reached 100%; Particularly noteworthy: • A 100% response rate was observed among PD-L1-negative patients; • Encouraging efficacy was also observed in elderly patients. Although longer follow-up is required, positive and consistent early efficacy signals are evident. Note: Enrollment is ongoing in the first-line all-comer squamous NSCLC (Chemo Combo) and first-line non-squamous NSCLC (Chemo Combo) cohorts. Data will be disclosed subsequently. V. Global Registration Strategy CS2009 is advancing through a global multi-regional clinical development pathway. • Rapid enrollment supports timely data package generation and regulatory engagement. • Registrational studies will not be conducted in a single country; all key registrational studies will be global multi-regional clinical trials (MRCTs) using current international standard-of-care comparators (pembrolizumab / pembrolizumab + chemotherapy / bevacizumab + chemotherapy). The trial designs and timelines are independent of data readouts from other bispecific/trispecific competitors, giving CS2009 a self-determined development advantage. - October 2026: Discuss the Phase III global registrational clinical trial protocol for first-line NSCLC + chemotherapy (vs. pembrolizumab + chemotherapy) . - Q4 2026: Discuss the Phase III global registrational clinical trial protocol for first-line mCRC + chemotherapy (vs. bevacizumab + chemotherapy) . - Early 2027: Discuss the Phase III global registrational clinical trial protocol for  second-line NSCLC (CS2009 + docetaxel vs. docetaxel) and first-line NSCLC monotherapy (head-to-head vs. pembrolizumab) . 20–60 patients of POC data are expected per indication. The company has already established a clinical, CMC (Chemistry, Manufacturing and Controls) and operational system that supports global development, laying the groundwork for subsequent global multi-center Phase III MRCTs . VI. Key Catalysts in 2026 • Late August 2026: Interim results update featuring more mature post-ASCO clinical data. • Around October 2026: FDA discussion regarding the Phase III global registrational clinical trial protocol for first-line NSCLC + chemotherapy. • Q4 2026: FDA discussion regarding Phase III global registrational clinical trial protocol for first-line CRC + chemotherapy. • Q4 2026: ESMO Congress – clinical data updates for CRC, NSCLC, and other indications. • End of 2026: Initiation of the first-wave global Phase III MRCTs. Importantly, all pivotal studies are benchmarked against current global standard-of-care comparators, without dependency on competitors’ development progress. VII. Business Development Progress In-depth discussions are ongoing with multiple multinational pharmaceutical companies (MNCs). Key areas of partner interest include: trispecific antibody design rationale, safety profile, clinical data in NSCLC and CRC, global registration strategy. As data continue to mature and the global development advances, the differentiated value of CS2009 is gaining increasingly broad and strong recognition. VIII. Management Confidence and Capital Markets Initiatives 1. Share Purchases by Management and the Board: Management and the Board believe that the recent share price volatility has significantly deviated from the Company’s fundamental progress. Management and Board members have expressed their confidence in the long-term value of CS2009 and the Company’s growth prospects by increasing their shareholdings. 2. Anticipated inclusion in the Hong Kong Stock Connect Scheme Management expressed a positive expectation that the Company will be included in the Stock Connect scheme at the September 2026 adjustment window. IX. Key Takeaway The ASCO 2026 data mark CS2009’s transition from mechanism validation to the clinical proof-of-concept (POC) stage. Its differentiated trispecific design not only delivers an excellent safety profile, but also consistently generates clinically meaningful efficacy signals and durable responses across a range of traditional I/O-cold tumors and lung cancer populations. As the key CRC and NSCLC programs move toward global registrational development, CS2009 is steadily emerging as a next-generation I/O backbone agent with significant potential. About CStone CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 21 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit: www.cstonepharma.com. IR contact: ir@cstonepharma.com PR contact: pr@cstonepharma.com Forward-looking statements The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments. Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes. 12/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 2026-06-12 / 15:02 UTC+8 ASCO 2026公布的多项临床数据进一步验证了CS2009的三靶点协同机制，并支持其作为新一代肿瘤免疫治疗（I/O）骨架药物的重要开发潜力。 一、三抗设计逻辑与差异化优势 1、相较VEGF联合PD-1具有更大的长期生存获益潜力，同时CTLA-4相关毒性低、耐受性良好 CS2009通过PD-1、VEGF和CTLA-4三靶点协同设计，旨在同时恢复T细胞效应功能、改善肿瘤微环境并增强T细胞初始激活，从而实现更深、更持久的抗肿瘤免疫应答。 • CTLA-4模块差异化设计：通过使外周CTLA-4单阳性T细胞免于过度激活，降低系统性免疫毒性，结合VEGF介导的肿瘤组织富集效应，在保留CTLA-4免疫激活作用的同时显著改善耐受性。临床数据显示，CS2009的CTLA-4相关毒性明显低于传统CTLA-4抗体治疗方案，免疫相关不良事件（irAE）发生率降至与PD-1单抗和双抗接近的水平。 • 持续给药优势：传统CTLA-4抗体通常仅能耐受两至三次给药，而CS2009可持续给药，从而更充分地发挥CTLA-4模块的作用。该模块不仅可以启动与增强对已存在的肿瘤抗原的免疫反应, 还能针对后续发生的新肿瘤抗原激活新的T细胞克隆，持续扩增抗肿瘤T细胞库。结合CS2009良好的耐受性，这一机制有望带来更持久的免疫应答，支持长期临床获益和延长患者生存。 • 药效学验证：观察到ICOS（T细胞活化标志物）呈剂量依赖性上升，作为CTLA-4通路活化后公认的药效学标志物，ICOS上调提示CS2009能够持续促进T细胞初始激活与克隆扩增，验证了其CTLA-4模块的生物学活性，并为长期抗肿瘤免疫应答提供生物学依据。 （行业挑战： 历史上多数抗VEGF联合PD-(L)1方案主要改善PFS，而OS获益存在较大不确定性。CS2009通过引入CTLA-4机制，力图突破这一局限。） 2、低VEGF相关毒性，支持更充分的治疗暴露和持续获益 药效学数据显示： • 给药后循环VEGF水平持续下降，经过147天随访仍未观察到明显反弹趋势。 这一现象与传统抗VEGF抗体或PD-1/VEGF双抗观察到的结果存在差异，可能与CS2009在肿瘤微环境中富集并通过CTLA-4介导内吞清除VEGF-抗体复合物有关，从而减少VEGF及其抗体结合复合物回流至外周循环，有助于降低高血压、蛋白尿等VEGF相关系统性毒性。 临床数据显示： • VEGF相关≥3级治疗相关不良事件（TRAE）发生率仅为5.1%，明显低于部分已报道的VEGF双抗方案。 （行业挑战：VEGF既是重要疗效驱动因素，也是联合治疗中主要毒性来源之一；高龄及高危患者毒性风险更高，可能影响生存获益。如何平衡疗效与耐受性，是VEGF赛道长期未解决的问题。） 3、冷肿瘤中持续观察到积极信号，体现CTLA-4模块潜在价值、验证三靶点协同机制 在多个传统I/O敏感性较低的瘤种中，包括：免疫治疗耐药非小细胞肺癌（NSCLC）、pMMR/MSS转移性结直肠癌（mCRC）、软组织肉瘤（STS）、非透明细胞肾癌（nccRCC），均观察到积极的临床活性。这一结果提示，CS2009通过同时阻断PD-1和CTLA-4，并结合VEGF机制，能够增强T细胞初始激活、扩展T细胞克隆谱、促进长期免疫记忆和持续抗肿瘤作用，同时改善肿瘤微环境中T细胞浸润，使免疫应答覆盖更多原本对I/O治疗不敏感的肿瘤。 多个冷肿瘤中的一致性疗效信号进一步支持，CS2009通过PD-1、CTLA-4和VEGF三靶点的协同作用，有能力重塑免疫抑制微环境，扩大免疫获益人群，并显示出突破传统PD-1单抗及PD-1/VEGF双抗疗效边界的潜力。 （行业挑战： 对于I/O不敏感冷肿瘤，目前仍缺乏真正有效的免疫治疗方案，PD-1联合CTLA-4仍是国际公认的重要突破方向之一。） 4、鳞癌与非鳞癌均观察到一致获益，体现广泛适用性 • 在NSCLC多个治疗场景中：鳞癌与非鳞癌患者均观察到相近缓解率。 CS2009目前显示出跨组织学亚型的一致获益趋势，提示其机制可能不依赖于特定病理类型，有望覆盖更广泛的NSCLC患者人群，并提高未来全球注册试验成功的确定性。 （行业挑战：鳞癌与非鳞癌之间往往存在明显的疗效差异，限制了部分产品的适应症拓展和商业化空间。） 二、安全性优势明确，VEGF毒性显著低于双抗 截至目前I期临床数据显示，在混合瘤种中（N=118）： • ≥3级TRAE发生率：24.6%； • ≥3级irAE发生率：12.7%； • VEGF相关≥3级TRAE发生率：5.1%。 聚焦NSCLC后线队列（n=57）的安全性： • ≥3级TRAE发生率：19.3%； • ≥3级irAE发生率：12.3%； • VEGF相关≥3级TRAE发生率：5.3%； 与I期多线经治混合瘤种人群整体的安全谱一致。 整体上： • CTLA-4相关毒性得到很有效的控制； • 未观察到非预期的安全性信号； • 整体安全性特征接近PD-1/VEGF双抗水平，VEGF毒性显著低于双抗。 这一安全性表现为后续长期给药和全球注册开发提供了重要基础。 三、疗效数据：冷肿瘤领域展现差异化价值 CS2009在多种难治性冷肿瘤中显示出有意义的临床活性，凸显其差异化的机制 1、结直肠癌后线单药（pMMR/MSS mCRC）： • 入组患者均为经治的难治性CRC，包括BRAF突变型和右侧结直肠癌； • CS2009单药：ORR 25%，DCR 87.5%。 考虑到传统后线治疗ORR通常仅为个位数水平，该结果已展现出具有临床意义的抗肿瘤活性。 更重要的是，疗效信号出现在典型I/O冷肿瘤人群中，进一步支持CTLA-4模块带来的潜在差异化价值。 2、一线联合XELOX治疗（pMMR/MSS mCRC）： • 研究未筛选左右半结肠、分子亚型或肝转移状态，入组人群更接近真实世界临床实践。 • 截至目前：6例患者均出现肿瘤缩小，3例首次疗效评估即达到PR • ORR 66.7%，DCR 100%。 虽然目前样本量仍然较小，但已观察到高度一致的早期疗效信号，为后续全球注册开发提供了积极支持。 公司计划继续扩大样本量至40例，以形成更完整的概念验证（POC）数据包，用于后续与包括美国食品药品监督管理局（FDA）和中国国家药品监督管理局（NMPA）在内的全球监管沟通III期全球注册临床试验方案。 3、其他冷肿瘤 • 软组织肉瘤（STS）后线单药：ORR 33.3%，DCR 66.7%； • 非透明细胞肾细胞癌（nccRCC）后线单药：ORR 33.3%，DCR 100%； • 患者疗效持久：I期首位患者（澳洲女性）12个月肿瘤持续缩小超40%。 四、NSCLC：多维度数据支持全球注册开发 维度一：后线NSCLC单药（IO/化疗/ADC/双抗经治） • 30mg/kg剂量组整体ORR 24%（鳞癌25%，非鳞癌23.1%，获益一致），DCR 60%； • 二线NSCLC（30mg/kg，IO+化疗经治）数据进一步提升：ORR 30.8%，DCR 84.6%。 在此类经PD-(L)1治疗后患者中，目前标准治疗ORR通常较低，因此CS2009已展现出具有竞争力的单药活性。 同时观察到： • 6个月缓解持续时间（DOR）率超80%（即超过80%的患者在6个月时仍能维持缓解）； • 患者缓解深度随时间持续增加； • DOR数据仍在持续成熟中。 维度二：后线NSCLC联合多西他赛 • 6例患者全部肿瘤缩小，ORR 66.7%，DCR 100%。 尽管目前样本量有限，但这一结果在同类研究中已非常具有竞争力。 公司计划进一步扩展至20例患者，以支持后续注册开发决策。 维度三：一线NSCLC单药（PD-L1 TPS≥50%） • 16例患者，ORR 81.3%，DCR 100%； • 鳞癌ORR 87.5%，非鳞癌ORR 75%，获益一致； • 较早时（2026年3月）数据显示10例患者有9例达到 PR，本次新增的6例患者有4例在首次肿评即达到PR，目前总共已观察到13例PR； • 所有应答患者均未出现快速进展，患者缓解深度随时间持续增加。 尽管跨研究比较存在局限性，但当前CS2009单药在一线NSCLC（PD-L1 TPS≥50%）中的ORR已达到国际同类研究中的领先水平（best-in-class range），显示出极具竞争力的临床开发潜力。 注：PD-L1 1%-49%人群数据仍在持续成熟中。 维度四：一线NSCLC联合化疗（鳞癌，PD-L1低表达/阴性） • 截至目前8例鳞癌患者中，7例均为PD-L1≤1%低表达/阴性，1例为PD-L1≤5%低表达，中位年龄70岁； • ORR 75%，DCR 100%；PD-L1阴性患者ORR达100%； 特别值得关注的是： • PD-L1阴性患者中观察到100%缓解率； • 高龄患者群体中同样观察到优异疗效。 尽管仍需更长时间随访验证，但已显示出积极且一致的早期疗效信号。 注：一线鳞状NSCLC联合化疗全人群、一线非鳞状NSCLC联合化疗仍在入组中，数据后续披露。 五、全球注册开发策略 CS2009正按照全球多中心开发路径推进。 • 入组速度极快，数据包准备节奏匹配，与监管沟通节点明确； • 不做单一国家注册研究，做全球多中心注册研究（MRCT），所有关键注册研究均采用国际标准治疗作为对照组（K药/K药+化疗/贝伐珠单抗+化疗），试验设计和时间窗口不受当前其他双抗/三抗竞品数据读出的干扰，具备独立推进的节奏优势。 - 2026年10月：与FDA沟通一线NSCLC联合化疗（对比K药+化疗）III期全球注册临床方案； - 2026年四季度：与FDA沟通一线mCRC联合化疗（对比贝伐珠单抗+化疗）III期全球注册临床方案； - 2027年初：与FDA沟通二线NSCLC（联合多西他赛头对头多西他赛）及一线NSCLC单药头对头K药的III期全球注册临床方案。 每个适应症需20-60例POC数据，目前公司已建立支持全球开发的临床、生产/工艺/质量（CMC）体系，为后续全球多中心III期MRCT研究奠定基础。 六、2026年重要催化剂 • 2026年8月底：中报更新ASCO后更成熟的临床数据； • 2026年10月左右：与FDA沟通一线NSCLC联合化疗III期临床试验方案； • 2026年四季度：与FDA沟通一线CRC联合化疗III期临床试验方案； • 2026年四季度：ESMO会议更新CRC、肺癌等适应症临床数据； • 2026年底：启动首批全球III期MRCT注册研究。 所有关键注册研究均采用当前国际标准治疗作为对照组，不依赖竞争产品研究进展。 七、BD进展 目前正与多家跨国药企（MNC）持续开展深入交流。合作方重点关注：三抗设计逻辑、安全性特征、NSCLC与CRC临床数据、全球注册开发路径。 随着数据持续成熟及全球开发计划推进，CS2009的差异化价值正得到越来越广泛和高度的认可。 八、管理层信心与市值管理 1、管理层及董事会增持： 近期股价波动明显偏离公司基本面进展。管理层及董事会表示，将通过增持公司股票表达对CS2009长期价值及公司发展前景的信心。 2、港股通纳入预期： 管理层表示，对公司于2026年9月调整窗口纳入港股通保持积极预期。 九、核心结论： ASCO 2026数据标志着CS2009已从机制验证阶段进一步迈向临床概念验证（POC）阶段。其差异化三抗设计不仅展现出优异的安全性特征，更在多个传统I/O冷肿瘤及肺癌人群中持续观察到具有临床意义的疗效信号与持久缓解。随着CRC和NSCLC关键项目推进全球注册开发，CS2009正逐步展露成为下一代肿瘤免疫治疗骨架药物的巨大潜力。 关于基石药业 基石药业（香港联交所代码: 2616）成立于2015年底，是一家专注于肿瘤、免疫与炎症等关键疾病领域药物研发的创新驱动型生物医药企业，致力于满足中国和全球患者的殷切医疗需求。截至目前，公司已成功上市4款创新药、获批21项新药上市申请（NDA）以及9项适应症。当前研发管线均衡配置了抗体偶联药物（ADC）、多特异性抗体、以及免疫疗法和精准治疗药物在内的16款候选药物。同时，基石药业拥有一支资深管理团队，“全链条”覆盖临床前探索、临床转化、临床开发、药物生产、商务拓展、商业运营等关键环节。如需了解有关基石药业的更多信息，请访问：www.cstonepharma.com。 投资者关系: ir@cstonepharma.com 媒体关系:pr@cstonepharma.com 前瞻性声明 本文所作出的前瞻性陈述仅与本文作出该陈述当日的事件或资料有关。除法律规定外，于作出前瞻性陈述当日之后，无论是否出现新资料、未来事件或其他情况，我们并无责任更新或公开修改任何前瞻性陈述及预料之外的事件。请细阅本文，并理解我们的实际未来业绩或表现可能与预期有重大差异。本文内所有陈述乃本文章刊发日期作出，可能因未来发展而出现变动。 声明：仅供医疗卫生专业人士交流使用。   2026-06-12 此财经新闻稿由EQS via SeaPRwire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php

EQS via SeaPRwire.com / 12/06/2026 / 09:50 UTC+8 Chicago, Illinois - June 12, 2026 - (SeaPRwire) - Lossdog, a new financial technology platform co-founded by Tom Sosnoff and Scott Sheridan, has officially launched in the United States with a mission to give working professionals access to the same quality of compensation data that employers have long used in salary negotiations. The platform offers a single, calculated dollar figure representing a user's professional market worth, expressed as annual salary. Sosnoff and Sheridan previously co-founded thinkorswim, an online brokerage specializing in options trading that was acquired by TD Ameritrade in 2009 for approximately $750 million. The two then co-founded tastytrade, a retail brokerage and financial media network acquired by IG Group in 2021 for $1.1 billion. Lossdog marks their third major fintech venture. The platform works by analyzing a user's resume against real labor market records, including government wage data, to produce a precise professional valuation. Lossdog also includes a portfolio optimization tool that evaluates a user's investment holdings and calculates the lifetime dollar value of underperformance relative to an industry baseline. Research published by Lossdog in early 2026 found that a professional starting at $75,000 per year could leave approximately $3.9 million in uncaptured nominal earnings over a 30-year career, a figure the company attributes to structural information asymmetry in wage negotiation. A follow-up report published in March 2026 found the gap to be significantly wider for female professionals. "Most professionals leave seven figures on the table over their careers because they're negotiating blind," said Jeff Joseph, Chief Strategist at Lossdog. "We built the first AI platform that reads your resume, analyzes your skills and experience against real data, and tells you what you're actually worth down to the dollar." To mark the platform's launch, Lossdog is offering free first-year subscriptions, valued at $100 each, to its first 50,000 registered users. Those users will also share in a $1 million cryptocurrency pool, with individual awards ranging from $50 for the earliest registrants to $10 for those in later waitlist positions. The company has reported more than 25,000 waitlist registrations. Lossdog operates in a space adjacent to platforms such as LinkedIn, Glassdoor, and Payscale, but distinguishes its product by generating an individual-specific figure rather than aggregated salary ranges. The platform currently serves users in the United States. "After 40-plus years on the trading side of the business world, we are about to take on a bigger challenge," Sheridan wrote publicly ahead of the launch. About Lossdog Lossdog is a Chicago-based financial technology company co-founded by Tom Sosnoff and Scott Sheridan. The company offers a subscription-based platform that uses artificial intelligence and government labor market data to calculate the precise professional market value of individual workers and to evaluate the performance of their investment portfolios. Lossdog is currently available to users in the United States. Contact Information Brand: Lossdog Contact: Jeff Joseph Email: jeff.joseph@lossdog.com Website: https://lossdog.com 12/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 11/06/2026 / 18:43 UTC+8 Results Highlights Chow Tai Fook Jewellery delivered strong FY2026 performance on the back of successful brand transformation, achieving high-quality earnings growth against macro uncertainties and significant gold price volatility. Revenue grew 5.3% to HK$94,398 million, underpinned by steady growth from design-led and higher-margin iconic collections. The Group achieved an operating profit of HK$18,850 million (+27.8% YoY) and a record high profit attributable to shareholders of HK$9,004 million (+52.2% YoY). Gross profit margin expanded to 32.3%, supported by higher gold prices and increased contribution from the retail business and design-led jewellery. Operating profit margin expanded 360bps to a five-year high level of 20.0% driven by strong business performance and continued disciplined cost management. Return on Equity ("ROE") increased to 28.4%, which represented a sustained improvement against our 5-year historical average of 20.5%. The Group opened its first global flagship store in Hong Kong in February 2026, alongside newly designed stores across the Chinese Mainland and key international markets, while expanding into luxury lifestyle categories. The Board has proposed a final dividend of HK$0.45 per share, bringing the full-year total to HK$0.67 per share, a payout ratio of 73.4%, reflecting our commitment to sustained shareholder returns.   Financial Summary   For the year ended 31 March 2026HK$ million 2025HK$ million YoY Change Revenue 94,398 89,656 +5.3% Gross profit 30,500 26,455 +15.3% Gross profit margin 32.3% 29.5% +280 bps Operating profit(1) 18,850 14,746 +27.8% Operating profit margin 20.0% 16.4% +360 bps Profit attributable to shareholders of the Company 9,004 5,916 +52.2% Earnings per share       Basic (HK$) 0.91 0.59 +53.7% Diluted (HK$) 0.90 0.59 +52.5% Full year dividend per share(2) (HK$) 0.67 0.52 N/A   (1)  Aggregate of gross profit and other income, less selling and distribution costs and general and administrative expenses (2)  The payout ratio for FY2026 approximated 73.4%   (Hong Kong, China, 11 June 2026) Chow Tai Fook Jewellery Group Limited (“Chow Tai Fook Jewellery Group”, the “Group” or the “Company”; SEHK stock code: 1929), today announces its annual results for the year ended 31 March 2026 ("FY2026").   Record Results Underscore the Continued Success of Brand Transformation The Group demonstrated strong resilience as revenue grew 5.3% to HK$94,398 million in a year marked by macroeconomic uncertainty and significant gold price volatility. Gross profit margin of 32.3% was up 280bps, driven by the surge in gold price and a higher contribution from the design-led and higher- margin iconic collections, successfully launched since 2024. Operating profit grew 27.8% to HK$18,850 million and profit attributable to shareholders grew 52.2% to a record high HK$9,004 million. Operating profit margin of 20.0% was up 360 bps to a five-year high level.   The Group’s Return on Equity ("ROE") increased to 28.4%, which represented a sustained improvement against our 5-year historical average of 20.5%. The Board has proposed a final dividend of HK$0.45 per share, bringing the dividend per share for the year to HK$0.67, a full-year payout ratio of 73.4%.  The strong performance was powered by a customer centric approach driven by three key levers of growth: (1) Redefining Chinese luxury globally, (2) Rejuvenating portfolio and operational efficiency and (3) Reimagining new horizons.   Dr. Henry Cheng, Chairman of Chow Tai Fook Jewellery Group, said, “We are committed to investing boldly in our brand – elevating desirability, forging deeper emotional connection with customers, and expanding our global resonance through immersive retail experience, exquisite craftsmanship, compelling storytelling and digital engagement that blends our rich heritage and cultural artistry with contemporary lifestyle.”   Commenting on the annual results, Ms. Sonia Cheng, Vice-chairman of Chow Tai Fook Jewellery Group, said, “We are delighted that the Group achieved record high results and high-quality earnings, validating the success of our brand transformation. As a leading global Chinese luxury group, Chow Tai Fook is charting a course to bring Chinese aesthetics, craftsmanship, and heritage storytelling to the world stage while setting a new benchmark for the industry.   Redefining Chinese Luxury Globally The global luxury landscape has been dominated by Western culture. Our ambition is to redefine Chinese luxury globally, showcasing the contemporary Chinese culture, innovation and exquisite craftsmanship to the world. The successful launch of our signature collection – DAWN Collection, has clearly demonstrated Chow Tai Fook’s innovation and creativity, being the first jewellery brand to blend Chinese aesthetics with modern craftsmanship. Since its launch in April 2026 till the end of May 2026, DAWN Collection has delivered remarkable initial results, with Retail Sales Value (“RSV”) of over HK$500 million, outperforming the debut of some of the signature collections to date. Furthermore, more than 20% of customers purchasing this Collection were new to us in the Chinese Mainland, Hong Kong and Macao, underscoring the effectiveness of our signature collections in driving new customer acquisition.   During the year, we unveiled our first High Jewellery Collection, “Timeless Harmony”, championing Eastern aesthetics through culturally rooted, world‑class craftsmanship and expanding the brand’s presence in the global high jewellery segment. In March 2026, we appointed David Tse as Global Creative Director, bringing deep luxury expertise from his tenure as Creative Director at Hermès in China, to lead our global storytelling and deepen brand desirability.   Blending heritage with contemporary designs, our signature collections continue to resonate with the growing base of culturally conscious consumers. The Rouge Collection, Joie Collection and Chow Tai Fook Palace Museum Collection sustained strong sales momentum in FY2026, contributing close to HK$10 billion to our RSV, while the iconic HUÁ Collection contributed HK$43 billion to our RSV.   Rejuvenating Portfolio and Operational Efficiency In February 2026, the Group opened its first global flagship store on Canton Road in Tsim Sha Tsui, Hong Kong, marking a significant milestone in its brand transformation journey. The approximately 10,000-square-foot flagship is the Group’s largest store across Hong Kong and Macao, showcasing the brand’s nearly century-long legacy, craftsmanship and creativity through it’s “Heritage Pavilion” and diverse offerings. The flagship offers consumers an elevated retail experience that reflects our evolving ambition as the leading global Chinese luxury group.   As of FY2026, we had a total of 8 newly designed luxury-format stores in prime locations in the Mainland. These stores delivered significantly higher productivity, which was approximately 8 to 10 times the average Same Store Sales (“SSS”). These newly designed stores also had a substantially higher contribution from fixed-price jewellery. We also selectively opened stores in high-footfall locations, backed by enhanced visual merchandising, optimised product mix and elevated retail experience. As a result, the average monthly RSV of new stores aged less than two years reached approximately HK$1.6 million, up 57% YoY. In view of the success of the newly designed luxury-format stores, we plan to expand its network in the Mainland from the current 8 stores to 50 by FY2030.   In the Mainland, SSS increased by 6.9% in FY2026, supported by our ongoing brand transformation initiatives and continued store optimisation. In Hong Kong and Macao, consumer demand strengthened notably post Mainland VAT reform on gold trading, with SSS rising 16.8% in FY2026. SSS growth in Hong Kong was 13.3% and Macao was 29.4% for the year.   During the year, the Group also advanced digitalisation and launched our in-house AI Agent platform, deploying over 12 agents across functions such as visual merchandising, the GenAI jewellery creative centre, and AI live streaming, to drive operational efficiency and enhance customer engagement.   Reimagining New Horizons The Group’s FY2030 ambition is to double the RSV of our international operations compared to FY2026; and to have an international footprint of over 100 stores.   In line with our ambition, the Group expanded the Chow Tai Fook universe into new geographies, channels, product categories, and experiences that resonate with the constantly evolving lifestyle and aspirations of customers in FY2026.   With the ambition to reshape global luxury and further strengthen our brand influence among global audiences, newly designed luxury-format stores were launched at Jewel Changi Airport in Singapore, Siam Paragon in Bangkok, and Westfield Sydney in Australia – marking our first entry into Oceania. This brings the total number of CHOW TAI FOOK JEWELLERY POS in Other Markets to 63. In FY2027, we will open further newly designed luxury-format stores across Southeast Asia and North America, while exploring opportunities in the Middle East in the next two years.   As the first global Chinese jewellery brand to enter the luxury lifestyle arena, the new luxury home-décor line “Chow Tai Fook Home” brings craftsmanship, cultural heritage and attention to detail to refined home décor and functional art, including tableware collections developed in collaboration with renowned French porcelain house Bernardaud, where Western craftsmanship meets Chinese cultural heritage and gold artistry. Together with CTF Accessories which covers hair adornments, gold medallions and watch strap accessories, the new lifestyle offers will capture diverse market segments, broaden our customer base and create synergies with our core jewellery business.   In FY2026, we continued to collaborate proactively with renowned IPs to reach new audiences. Our Black Myth Collection received overwhelming market response, with a significantly higher male mix than the Group average. Meanwhile, collaborations with Disney, Chiikawa and the NBA attracted new loyalty members, which accounted for 35%–55% of these IP collaborations’ customers, with a significant percentage of younger generations. HEARTS ON FIRE, a member of the Group, has continued its transformation into a modern global luxury diamond jewellery brand within the Group. During the year, HEARTS ON FIRE delivered resilient performance with its iconic INSIDE/OUT Collection contributing to 13% of the brand’s global revenue. The brand also expanded its retail presence in Asia with five new luxury retail locations, strengthening visibility in key luxury markets.   Business Outlook The strong financial and operational performance highlights the success of our brand transformation strategy and paves the way for further growth.   We are now entering the definitive phase of our multi-year transformation journey to our centenary in 2029, accelerating the pace and ensuring the precision of our full-scale strategic execution in FY2027 and beyond. Our sharpened focus is on elevating brand desirability, enriching the retail experience, and strengthening product differentiation.   Despite continuing external market volatility and macroeconomic uncertainty, we remain cautiously optimistic in the markets where we operate. We are firmly committed to our brand transformation journey – redefining Chinese luxury globally, rejuvenating portfolio and operational efficiency and reimagining new horizons.   We will continue to rigorously uphold financial discipline in cost and capital management, driving high-quality growth, sustainable earnings and returns for our shareholders.   FY2030 Ambitions As we approach our centenary, we envision a Chow Tai Fook universe where jewellery seamlessly intertwines with the lifestyle of our customers – enriching their appreciation of cultural heritage, artistry, and craftsmanship. We see luxury as a universal language that transcends borders and cultures, where jewellery and lifestyle come together to express a shared vision of beauty, elegance, and creativity.   Looking ahead to FY2030, we have set out the following ambitious targets: Financial performance: We aim to achieve above-market revenue growth, and sustain a high ROE of above 25% by FY2030; Store network evolution: We target to complete the full renovation and elevation of our POS portfolio by FY2030, delivering a cohesive and distinctive retail experience across all locations. In parallel, we plan to expand our network of newly designed luxury-format stores in the Mainland from the current 8 stores to 50 by FY2030; International expansion: We aim to double the RSV of our international operations compared to FY2026; and to have an international footprint of over 100 stores. Sustainability: We will target a 50% reduction in Greenhouse Gas emissions by FY2030, using FY2024, the first year of our brand transformation journey, as the base year. ###   Chow Tai Fook Jewellery Group Limited Since its founding in 1929, CHOW TAI FOOK, the flagship brand of Chow Tai Fook Jewellery Group, has been celebrated for its bold designs and meticulous attention to detail. Our commitment to innovation and craftsmanship has made us synonymous with excellence, value, and authenticity. As the global Chinese luxury group, we blend contemporary designs with traditional techniques to create timeless pieces. Each collection reflects our customers' stories and lives, celebrating their special moments. We aspire to inspire and captivate generations to come, weaving the story of CHOW TAI FOOK into their own. Our brand portfolio includes the iconic CHOW TAI FOOK flagship brand, HEARTS ON FIRE, ENZO, and MONOLOGUE, offering a wide variety of products that also includes an expanding range of cutting-edge IP collaborations. With over 5,000 stores worldwide, we offer a seamless client journey across all touchpoints that includes a network across China as well as a growing number of global locations. Chow Tai Fook Jewellery Group Limited (SEHK: 1929) has been listed on the Main Board of the Hong Kong Stock Exchange since December 2011. We are committed to delivering sustainable long-term value for our stakeholders by continually enhancing earnings quality and driving higher value growth.   Media Enquiries: Chow Tai Fook Jewellery Group Limited   Haide Ng Associate Director, Corporate Communications Tel: (852) 3115 4402 Email: haideng@chowtaifook.com 11/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 2026-06-11 / 18:43 UTC+8 业绩重点 2026财政年度，在品牌转型的持续推动下，本集团录得强劲业绩。尽管外部不确定性升温，以及黄金价格出现前所未见的波动，集团仍实现高质量盈利增长。 营业额按年增加5.3%至94,398百万港元，主要受惠于设计独特、高毛利的标志性产品系列销售贡献提升。 期内，集团录得经营溢利按年增长 27.8% 至 18,850 百万港元，股东应占溢利增加52.2%至9,004百万港元，创历史新高。 毛利率提升至32.3%，乃受惠于黄金价格飙升以及销售组合转向较有利的零售业务及设计独特的首饰。加上强劲业务表现及严谨的成本控制，经营溢利率提升360个点子至20.0%，创近五年新高。 本集团的股本回报率上升至28.4%，较过往五年的历史平均水平20.5%持续提升。 2026年2月，集团于香港开设首间全球旗舰店，并相继于中国内地（内地）及主要国际市场开设新设计门店，同时将业务拓展至奢华生活时尚领域。   董事会建议派发末期股息每股 0.45 港元，连同中期股息，全年股息每股共 0.67 港元，派息率达 73.4%，反映集团对持续为股东创造回报的坚定承诺。   财务摘要   截至3月31日止年度 2026百万港元 2025百万港元 同比变化 营业额 94,398 89,656 +5.3% 毛利 30,500 26,455 +15.3% 毛利率 32.3% 29.5% +280 个点子 经营溢利(1) 18,850 14,746 +27.8% 经营溢利率 20.0% 16.4% +360个点子 本公司股东应占溢利 9,004 5,916 +52.2% 每股盈利       基本（港元） 0.91 0.59 +53.7% 摊薄（港元） 0.90 0.59 +52.5% 每股全年股息(2) （港元） 0.67 0.52 N/A   (1)毛利及其他收入的合计，减销售及分销成本以及一般及行政开支(2)2026财政年度全年度的派息率约为73.4%  （中国香港, 2026年6月11日） 周大福珠宝集团有限公司（「周大福珠宝集团」、「周大福珠宝」、「集团」或「公司」；香港联交所股份代号︰1929）今天宣布截至2026年3月31日止年度的全年业绩（「2026财政年度」）。 业绩创历史新高 充分彰显品牌转型成效 2026 财政年度，全球宏观经济持续不明朗，金价亦录得前所未有的波动。尽管面对这些挑战，集团展现坚实韧性，营业额按年增加5.3%至94,398百万港元。毛利率上升280个点子至32.3%，乃受惠于黄金价格大幅度波动，以及自2024年起成功推出设计独特、高毛利的标志性产品系列销售贡献提升所带动。经营溢利增长27.8%至18,850百万港元，股东应占溢利增加52.2%至9,004 百万港元，创历史新高。经营溢利率上升360个点子至20.0%，创五年新高。   集团的股本回报率上升至28.4%，较过往五年的历史平均水平20.5%持续改善。董事会建议派发末期股息每股0.45港元，全年股息每股共0.67港元。2026 财政年度全年派息率约为73.4%。强韧的表现由以客为本的策略及三大关键增长动力所推动：（1）重塑中国奢侈品牌的全球地位、（2）强化产品组合及营运效率，以及（3）开拓新领域。   周大福珠宝集团主席郑家纯博士表示：「我们积极加大品牌投入，持续提升品牌吸引力，深化与顾客之间的情感连结，并透过沉浸式零售体验、精湛工艺及富有感染力的叙事，进一步与全球消费者建立更深共鸣，以及藉数字化互动，展现品牌如何将深厚的历史与文化艺术底蕴，融汇于当代品味生活之中。」   就全年业绩而言，周大福珠宝集团副主席郑志雯女士表示：「我们欣然见到集团录得历史新高业绩及高质量盈利，充分印证品牌转型的成效。作为全球知名中国奢侈品集团，周大福将中式美学、精湛工艺与深厚文化底蕴引领到世界舞台，并为行业树立新标准。」   重塑中国奢侈品牌的全球地位 全球奢侈品市场一直由西方文化主导。我们致力重塑全球奢华格局，向世界展现当代中国文化、创造力与卓越工艺。周大福成功推出标志性的万相系列，充分展现品牌的创新技术及设计创意，成为首个将中国美学与现代工艺巧妙融合的珠宝品牌。万相系列一经面世即引发市场热烈追捧，自今年4月开售以来至5月底，的零售值已超过5亿港元，比部分标志性产品系列开售初期成绩更为出众。另外，标志性产品系列亦发挥吸纳新客群的关键作用。例如在内地及港澳市场，购买万相系列的顾客当中，有超过20%为新客。年内，我们推出首个高级珠宝系列「和美东方」，透过植根于文化的世界级工艺弘扬东方美学，并进一步提升品牌在全球高级珠宝领域的影响力。2026 年 3 月，集团委任谢鼎鸿（David Tse）为全球创意总监。他曾任爱马仕驻中国创意总监，累积了丰富的奢侈品专业经验，将引领集团的全球故事叙述，进一步深化品牌吸引力。   我们亦持续丰富标志性产品系列，进一步强化品牌差异化。2026 财政年度， 传福系列、传喜系列及周大福故宫系列等标志性产品系列保持强劲销售势头，合共贡献集团零售值近100亿港元，而经典的传承系列则贡献了集团零售值达430亿港元。   强化产品组合及营运效率   今年2月，集团于香港尖沙咀广东道开设全球首间旗舰店，标志着品牌转型之旅的重要里程碑。该旗舰店占地约10,000 呎，是集团在香港及澳门面积最大的门店。此店特设「品牌典藏馆」，完美展现我们的历史文化、工艺及创造力。该旗舰店为顾客带来升级的零售体验，体现我们作为世界知名中国奢侈品集团的抱负。   截至2026 年财年底，我们在内地的黄金地段共设8 间新设计的高端形象门店。该等门店的生产力约为平均同店销售的8 至10 倍，当中定价首饰带来的贡献增幅尤其明显。除了这种店型，我们亦精挑人流畅旺的地段开设门店，同时优化视觉陈列、产品组合及零售体验。店龄不足两年的新店平均每月零售值达约1.6 百万港元，较去年同期大幅增长57%。鉴于新设计的高端形象门店取得理想成效，我们计划于中国内地开设更多该类门店，由目前的8 间扩展至2030 财政年度的50 间。   内地方面，我们持续推动品牌转型及优化门店措施， 2026 财政年度的同店销售上升6.9%。在香港及澳门，内地推行黄金增值税新政策后，消费者需求显著增强，2026 财政年度同店销售增长达16.8%。年内，香港同店销售增长为13.3%，澳门则为29.4%。   年内，集团进一步加强数字化进程及推出内部开发的AI 智能体平台。我们已于各关键职能部门部署超过12 个AI 智能体，涵盖门店视觉陈列、生成式人工智能珠宝创意中心和人工智能直播等领域，以提升营运效率并优化顾客互动体验。   开拓新领域 集团为2030 财政年度订立了远大的目标，包括相较2026 财政年度，将国际业务的零售值提升一倍，并把国际版图扩充至100 间门店以上。   配合集团的抱负，我们于2026 财政年度进一步将周大福品牌宇宙拓展至新地域、新渠道、新产品类别及体验，以契合顾客不断演变的生活时尚与追求。   本着重新定义全球奢侈品、进一步强化品牌对全球消费者影响力的抱负，集团相继于新加坡星耀樟宜机场、曼谷暹罗百丽宫，以及首个大洋洲的零售据点 ─ 澳洲悉尼西田购中心开设新设计的高端形象门店，带动周大福珠宝于其他市场的零售点总数增加至 63 个。2027 财政年度，集团将继续于东南亚及北美开设更多新设计的高端形象门店，并于未来两年探索中东市场的发展机会。   集团作为首个进军奢侈生活时尚领域的全球知名中国珠宝品牌，透过「周大福家居」将工艺、文化传承及对细节的极致追求，延伸至精致的家居装饰与功能性的艺术品之中，包括与知名法国高级瓷器世家Bernardaud 合作推出餐具系列，精妙融合西方工艺与中国文化传承及黄金艺术。   我们亦推出包括发饰、金章及表带配饰在内的「周大福配饰」，策略性地拓展产品类别。该等生活时尚产品组合旨在开拓多元化的细分市场、扩大客群，并吸引及接触新顾客，同时与我们的核心珠宝业务产生强大的协同效应。   2026 财政年度，我们持续积极推动与知名IP跨界合作，以触及更广泛的新客群。我们与《黑神话》的联乘系列广受市场热烈欢迎，其男性顾客占比显著高于集团平均水平。同时，集团与迪斯尼、Chiikawa及NBA的联乘项目亦成功吸纳新会员，相关IP产品的顾客中约有35%至55%为新会员，当中不乏年轻一代。 集团旗下的HEARTS ON FIRE 于年内持续推动转型，巩固其作为当代钻石珠宝品牌的定位。品牌年内展现稳健表现，其标志性 INSIDE/OUT 系列贡献品牌全球收入的 13%。同时，品牌亦新增5个零售点以拓展亚洲零售版图，进一步在多个重点奢侈品市场提升知名度。   业务展望 集团品牌转型策略的成效，充分体现在2026 财政年度稳健的财务及营运表现，以及2027 财政年度至今持续展现的韧性。   我们现正迈入数年转型旅程中的关键阶段，朝着2029 年百年里程碑迈进。我们将于2027 财政年度及其后加快步伐，并确保策略执行更具精准度与全面，重点聚焦于提升品牌吸引力、优化零售体验及加强产品差异化。   尽管外部环境仍存在波动及宏观经济不确定性，我们对所营运市场持审慎乐观态度。我们将坚定推进品牌转型进程 – 重塑中国奢侈品牌的全球地位、强化产品组合及营运效率，以及开拓新领域。   集团将持续严格执行财务纪律，加强成本及资本管理，推动高质量增长，并为股东创造可持续的盈利及回报。   2030 财政年度的抱负 在品牌迈向百年里程碑之际，我们正致力构筑一个以珠宝融入顾客品味生活的周大福品牌宇宙，进一步深化顾客对文化传承、艺术美感与精湛工艺的欣赏与共鸣。我们深信，奢华是一种跨越地域与文化的共通语言，而珠宝与品味生活的融合，正是对美学、优雅与创意的共同诠释。   展望2030年，我们为订立了以下目标： 财务表现：我们旨在实现高于市场的营业额增长，并于2030财政年度维持25%以上的高股本回报率； 门店网络升级：我们计划于2030 财政年度完成零售点的全面翻新与升级，务求在所有地点提供一致且具备鲜明特色的零售体验。同时，我们计划于中国内地开设更多新设计的高端形象门店，数量将会从目前的8间大增至2030 财政年度的50 间； 扩张国际市场：目标将国际业务的零售值较2026 财政年度提升一倍，并将国际市场门店扩张至逾 100 间； 可持续发展：我们的目标是以2024 财政年度，即我们品牌转型的起始年度为基准年，于2030 财政年度前将温室气体排放量减少50%。   ###   关于周大福珠宝集团有限公司 周大福珠宝集团的旗舰品牌「周大福」创立于1929年，一直透过别出心裁的设计和对细节的坚持，让传统成为经典。时至今日，品牌已成为了卓越品质、非凡价值及诚信可靠的代名词。   作为全球知名中国奢侈品集团，我们深信透过现代创新设计揉合传统工艺，能创造出代代相传的臻品。每个系列皆承载顾客的人生故事，庆祝他们生命中每个珍贵时刻，并在追寻幸福的旅程中带来启发和激励，让「周大福」的品牌故事深深融入顾客的生活脉络。   集团拥有丰富的品牌组合，除了旗舰品牌「周大福」，还有HEARTS ON FIRE、ENZO与MONOLOGUE。我们亦积极开拓IP 联乘合作，为顾客提供多元化的选择。我们的业务网络遍布中国，且持续延伸至全球多个市场。在全球设有逾5,000 家门店，致力于全渠道为顾客提供无缝体验。   周大福珠宝集团有限公司（香港联交所股份代号：1929）于2011 年12 月在香港联合交易所主板上市，致力通过提高盈利质量和推动更高价值的增⾧，为不同持份者创造可持续的⾧期价值。     传媒垂询，请联络： 周大福珠宝集团有限公司吴海廸（Haide Ng） 企业传讯副总监 电话：（852）3115 4402 电邮：haideng@chowtaifook.com 2026-06-11 此财经新闻稿由EQS via SeaPRwire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php

EQS via SeaPRwire.com / 09/06/2026 / 16:00 UTC+8 (9 June 2026, Hong Kong) Waton Financial Limited Unveils MoTA: An AI-Native Investment Team Operating System and Agent Marketplace That Lets Anyone Build, Manage, and Command Their Own Professional Investment Research Team Waton Financial Limited today unveiled MoTA (Manager of Trading Agents), an AI-native investment team operating system and Agent marketplace that redefines what AI can do for investors. MoTA is not a stock-picking chatbot or a black-box trading bot. It is a platform designed to let users build, manage, and command their own team of specialized AI Agents across the full investment workflow — from portfolio definition to trade execution. The Problem Professional investment research has always required a team: factor researchers, fundamental analysts, technical analysts, risk managers, portfolio constructors, and trade execution officers. Each role demands specialized talent and expensive infrastructure. For individual investors and small teams, assembling such a capability has been cost-prohibitive — until now. The Solution MoTA transforms the user from a passive consumer of AI signals into an active leader of an AI-powered investment team. Its four integrated modules work together to deliver a seamless, end-to-end experience. First, Talents — the Agent Marketplace. Users browse, compare, and hire specialized AI Agents by role. Each Agent is purpose-built for a specific investment function — fundamental analysis, technical analysis, risk management, trade execution, and more. Agents can be swapped and composed as strategies evolve. Second, Team — composing your investment team. Users assemble multiple Agents into a structured team. Analysts feed research inputs, the Portfolio Manager evaluates and writes memos, the Risk Manager reviews exposure, and the Trader validates routing. The human user retains final sign-off authority at every stage. Third, Portfolio — the portfolio cockpit. A real-time overview of holdings, assets, P&L, risk, and exposure. Users see exactly what is moving across positions, where risk sits, and where returns originate — all in one unified view. Fourth, Decision — the Decision Center. Every Agent-generated suggestion surfaces in the Decision Center with full context: source Agent, signal, reasoning, and current status. Users can click into the full workflow or execution path, compare competing analyses, and manage an actionable queue of decisions. Every recommendation is structured, traceable, and auditable. These four modules connect in a continuous workflow: Portfolio to Decision to Team to Trade. Why MoTA Is Different Traditional AI investing tools offer a single AI chat box, scattered research answers, black-box signals, no role separation, and AI value that is hard to measure. Reviews are tied to AI silos. MoTA provides a multi-Agent investment team, a connected Portfolio-to-Trade workflow, an auditable Decision Center, dedicated Analyst and PM and Risk and Trader roles in coordination, unified metrics such as ROI and win rate and cost per run and override rate, and a unified path for portfolio, decisions, Agents, and trades. The Vision Behind MoTA Waton Financial Limited's mission with MoTA is clear: to make professional-grade multi-agent investing tools more accessible, more transparent, and more user-controlled. MoTA does not replace human judgment — it amplifies it. The platform frees users from the burden of being a full-stack investment expert and elevates them to a higher role: the builder, manager, and decision-maker of their own AI investment team. As AI moves from content generation into workflow execution, investing — inherently a multi-role, multi-step, multi-constraint process — is a natural fit for this transformation. MoTA is designed to bridge the gap between what AI can do and what the investment workflow actually needs. About MoTA MoTA (Manager of Trading Agents) is Waton Financial Limited's flagship AI-native investment team operating system and marketplace for specialized investing Agents. It enables users to create fully customizable investment teams, assign specialized AI Agents to each role, and receive structured, traceable, and auditable investment suggestions across the entire Portfolio-to-Trade workflow. About Waton Financial Limited Waton Financial Limited is a publicly listed financial services and technology company that designs, owns, and operates the MoTA platform. Waton is committed to building AI-native infrastructure for investment teams and making professional-grade multi-agent investing tools accessible to a broader audience. Welcome to MoTA. Welcome to the new era of investing.   Media Contact Email: ir@watonfinancial.com Website: https://wtf.us Explore MoTA: https://mota.ai   Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those expressed or implied. This is not investment advice. Past performance does not guarantee future results. 09/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 08/06/2026 / 10:13 UTC+8 On June 5, 2026, C.banner (01028.HK) announced that it will obtain controlling interests in Benyuan Zhishu, a leading domestic AI data service provider, through equity acquisition and new share subscription.  Benyuan Zhishu will be consolidated into the Group’s financial statements, marking the formation of a dual-core business structure comprising “footwear+ Artificial Intelligence data”.   Why data?  As public data is gradually digested by large models, the critical bottleneck in AI is shifting from “whose model is bigger” to “who can continuously provide harder, more authentic, high-quality data.”  Computing power can be purchased, algorithms can be replicated, but this particular task cannot be bought or expedited.  In 2025, Meta invested in Scale AI at a valuation of approximately $29 billion, marking a market revaluation of this insight.    The scarcity of  Benyuan Zhishu lies in its position and profitability.  Founded in 2015, it sits upstream in the AI industry chain and is one of the few domestic suppliers that possess comprehensive data service capabilities, including large models, world models, and embodied intelligence. It serves top-tier large model manufacturers, leading internet platforms, and eminent embodied intelligence enterprises, acting as an exclusive supplier in several high-value data categories.  Its revenue in 2025 was approximately 156.2 million yuan, with a net profit of 11.1 million yuan after tax, and the first five months of 2026 have shown strong revenue growth.  In an AI industry largely reliant on burning money, a data company equipped with real orders and already profitable is indeed rare.    The design of this transaction also demonstrates ingenuity: it is funded entirely with the Group’s internal resources. C.banner’s footwear business generates solid cash flow and maintains a net cash position. Proceeds from the new share subscription will be invested into capacity expansion and R&D, while the founding team will retain equity holdings. Upon completion of the transaction, Benyuan Zhishu will retain its independent brand, independent operations, and data segregation. C.banner will not develop models or compete with Benyuan Zhishu’s clients, allowing industry competitors to continue using the same neutral supplier with confidence.    The management of C.banner stated: “We believe that high-quality data is one of the most critical and scarce infrastructures in the era of artificial intelligence. This transaction allows the Group to enter this rapidly growing sector while maintaining a stable foundation in the consumer industry. We look forward to working with Benyuan Zhishu to continuously provide 'data fuel' of high quality to China's AI industry, creating sustainable long-term value for our shareholders under the dual-core business framework.” 08/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 04/06/2026 / 19:30 UTC+8 [Hong Kong – 4 June 2026] Newborn Town Inc., a leading global social entertainment company (Newborn Town or the company, stock code: 09911.HK) is pleased to announced that it has cancelled a total of 5,174,000 shares repurchased between 27 April  and 29 May 2026, representing an aggregate repurchase consideration of approximately HK$45.32 million.   Prior in March 2026, Newborn Town announced a share repurchase plan of approximately HK$300 million to be carried out over the next two years. According to the announcement, following this cancellation, the total number of issued shares will decrease from 1,413,208,391 to 1,408,034,391, and Newborn Town will no longer hold any treasury shares.   The Board believes that the cancellation of the repurchased shares will enhance net asset value per share and earnings per share, which aligns with the overall interests of the Company and its shareholders. The Board will continue to review and, at its sole discretion, execute share repurchases from time to time. The Company’s continued execution of both share repurchases and share cancellations sends a clear signal of management’s confidence in Newborn Town’s long-term growth prospects, while also demonstrating its commitment to enhancing shareholder returns and improving capital efficiency.   Since its inclusion in the Stock Connect in March this year, Newborn Town has seen a significant increase in trading activity, accompanied by growing participation from Southbound investors. Notably, the latest round of repurchases was conducted shortly after the release of the Company's first quarter operating update. On 22 April, Newborn Town announced its unaudited operating data for the first quarter of 2026. During the period, total revenue is expected to reach approximately RMB2,030 million to RMB2,130 million, representing a year-on-year increase of approximately 33.0% to 39.6%. Among this, revenue from social networking business increased by approximately 31.3% to 37.2% year-on-year, while revenue from innovative business surged by approximately 46.7% to 58.7%, primarily driven by the rapid expansion of its AI-powered short drama business.   About Newborn Town  Newborn Town has grown into a leading technology company which was listed on the Main Board of the Hong Kong Stock Exchange (HKEX) in 2019 under the stock code 9911.Committed to creating positive emotional value worldwide, Newborn Town has developed a diverse portfolio of applications in the social networking and entertainment sectors. Its social apps include MICO, YoHo, TopTop, SUGO and HeeSay, together with gaming products like Alice's Dream: Merge Games. These applications have achieved widespread acclaim, reaching over one billion users in over one hundred countries and regions.Newborn Town considers the Middle East and North Africa (MENA) region a key market and has also extended its influence in Southeast Asia, Europe, the United States, Japan, and South Korea. The company aims to become the world's largest social entertainment company.      For enquiries, please contact  DLK Advisory   pr@dlkadvisory.com    04/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 2026-06-04 / 19:30 UTC+8 6月4日，赤子城科技发布公告称，公司已注销此前于2026年4月27日至5月29日期间购回的合共517.4万股股份，涉及总回购金额约4532万港元。   此前，赤子城科技于2026年3月宣布，计划未来两年斥资约3亿港元在市场上进行股份回购。公告显示，本次注销后，赤子城科技已发行股份总数将由14.13208391亿股减少至14.08034391亿股，公司不再持有任何库存股份。   赤子城科技董事会表示，注销购回股份将提高每股股份资产净值及每股股份盈利，符合公司及股东整体利益，董事会将继续不时检讨及全权酌情决定进行股份购回。公司近期已连续推进回购及注销动作，向市场释放出管理层对公司长期发展前景的信心，也体现出其对股东回报和资本效率的重视。   自今年3月纳入港股通以来，赤子城科技累计成交额大幅提升，南向资金参与热情持续升温。从回购时点看，此轮回购正值公司一季报发布后。4月22日，赤子城科技披露2026 年第一季度未经审核营运数据，期内总收入预期约20.30 亿~21.30亿元人民币，同比增长约33.0%~39.6%。其中，核心社交业务同比增长约31.3%~37.2%；创新业务同比增长约46.7%~58.7%，主要得益于AI驱动下短剧业务的快速增长。 2026-06-04 此财经新闻稿由EQS via SeaPRwire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php

EQS Newswire / 03/06/2026 / 11:12 UTC+8 From Cell to System. From proven manufacturing experience to localized European support. Not only broad technology coverage, but the operational stability you can depend on. June 9–11, 2026 | Booth 1-B30 European battery manufacturers are moving beyond equipment procurement toward industrial ramp-up, where yield, uptime, process discipline, and local service capability determine long-term competitiveness. As battery manufacturing moves from pilot validation toward industrial-scale production, operational reliability is becoming increasingly critical across the industry. At The Battery Show Europe 2026, Hymson returns for its fifth consecutive year with a clear message for the European market: “How we make it reliable.” From process validation to mass production. Battery industrialization is not only about installing equipment. It requires process validation, operator training, spare parts readiness, data visibility, and continuous improvement mechanisms. Over the past five years, Hymson has continued to deepen its engagement with the European market, working alongside battery manufacturers amid evolving production demands, technology transitions, and industrial-scaling challenges. This long-term collaboration has enabled Hymson to continuously refine both its technologies and manufacturing methodologies for global battery production environments. Behind this commitment is sustained investment in innovation and engineering capability. By 2025, Hymson’s cumulative R&D investment will reach USD 86 million, with 34.47% of employees dedicated to R&D. Total operating revenue is projected to reach USD 939 million in 2026, supporting continued advancement in next-generation battery manufacturing technologies and industrial delivery capability. Mid-Section Turnkey Solutions for Scalable Manufacturing At Booth 1-B30, Hymson will present its latest Mid-Section Turnkey Solution through a comprehensive product matrix and a series of scaled technology models showcasing key manufacturing innovations, alongside extensive battery process samples demonstrating end-to-end manufacturing capabilities. The scaled equipment models on display include: Solid-State Dry-Electrode Solution Film-Forming & Calendering & Lamination Integrated Machine  390 High-Speed Cutting & Stacking Machine CT Inspection Machine for Prismatic Assembly Through these scaled technology models, Hymson will provide visitors with a more intuitive understanding of process integration, equipment architecture, and manufacturing workflow within next-generation battery production environments. Hymson will also showcase: 588Ah Cell Samples Developed for Overseas Customer Requirements 588Ah Cell Cap & Can Laser Welding Samples 40+ process samples covering electrode manufacturing, surface treatment, prismatic assembly, and stacking technologies Together, these exhibits reflect Hymson’s integrated approach to mid-section manufacturing — combining process capability, operational consistency, and scalable production performance. Reliability Starts from Cell Design For Hymson, manufacturing reliability does not begin at equipment installation or even at mass production. It begins much earlier — at the cell design and manufacturability assessment stage. To support customers throughout the entire industrialization journey, Hymson provides an integrated consulting and engineering support framework covering: Cell Design to Manufacturing Production Line Planning Mass Production Line Ramp-up Support Training A key focus within this framework is manufacturability validation before mass production. For many next-generation battery technologies, laboratory-level performance alone is not sufficient for successful industrialization. To reduce scaling risks, Hymson provides DOE (Design of Experiments) and DTM-based battery process analysis to support parameter optimization, blueprint evaluation, and manufacturability feasibility study. Through this process, Hymson helps customers establish: Optimized Process Parameters Manufacturable Battery Analysis Stable Transition from Validation to Mass Production Reduced Ramp-Up Uncertainty and Operational Risks Hymson helps customers translate validated pilot-line conditions into scalable mass-production workflows with thousands of successful delivery and implementation experiences as lessons learned, transitioning into Know-How for the customers, enabling smoother and more accurate alignment between pilot validation and large-scale production environments. This approach helps minimize the risks of industrialization while accelerating mass-production readiness. Technical discussions and in-depth solution exchanges will be available throughout the exhibition. Digitalized Operations for Long-Term Stability Beyond manufacturing equipment, Hymson will also present its End-to-End intelligent manufacturing support across equipment, logistics, and operations management This includes Hymson’s intelligent warehousing & logistics solution together with the IEMS intelligent equipment operation and maintenance system. Driven by AI algorithms and 3D visual monitoring technologies, the system enables: Digital Closed-Loop Production Real-Time Operational Visibility Intelligent Equipment Maintenance Data-Driven Production Management Dark-Factory-Oriented Operation Scenarios The system supports higher levels of automation and unmanned operation where applicable by integrating manufacturing execution, logistics coordination, and equipment operation into a unified system, Hymson helps customers improve operational transparency, production efficiency, and long-term factory stability. Spare Parts Support Built Around Operational Continuity To further strengthen production reliability, Hymson continues to enhance its global spare parts service capability. Hymson provides both original Hymson spare parts and third-party qualified industrial spare parts, tailored to customer requirements, supported by flexible supply mechanisms and predictive inventory planning. The service framework helps customers secure: Critical Spare Parts Availability Improved Price and Lead-Time Predictability Reduced Downtime Risks Lower Inventory Burden Where Applicable Optimized Total Cost of Ownership (TCO) Through data-driven spare parts forecasting and scheduled replenishment systems, Hymson aims to establish a replicable, stable after-sales support structure for long-term manufacturing operations. Advancing Reliable Battery Manufacturing from Asia to Europe Returning to The Battery Show Europe 2026 for the fifth consecutive year reflects Hymson’s long-term commitment to supporting Europe’s battery manufacturing ecosystem. From process development to intelligent factory operations, Hymson continues to combine large-scale manufacturing experience from Asia with localized industrial collaboration in Europe — helping battery manufacturers build production systems designed not only for technological advancement but also for reliable long-term operation. As Hymson has always stated, visitors are invited to discuss specific challenges such as process validation, ramp-up risk reduction, equipment OEE improvement, spare parts planning, and localized service support. Company： Hymson Laser Technology Group Co., Ltd. Contact Person:  liruiyu Email: liruiyu@hymson.com Website:  https://www.hymson.com 03/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News. The issuer is solely responsible for the content of this announcement. Media archive at www.todayir.com View original content: EQS News

EQS via SeaPRwire.com / 04/06/2026 / 11:06 UTC+8 Hong Kong - June 03, 2026 - (SeaPRwire) - Southeast Asia is becoming a new engine of global economic growth, with Indonesia, Thailand, and Vietnam acting as the most dazzling "vibrant troika" among them. To help global enterprises seize the dividends of the Southeast Asian market, renowned media service provider SeaPRwire (https://seaprwire.com) announced today that it has successfully and deeply tapped the local mainstream media ecosystems of Indonesia, Thailand, and Vietnam, building a PR green channel reaching hundreds of millions of consumers in Southeast Asia directly for overseas enterprises. Indonesia's demographic dividend, Thailand's consumer vitality, and Vietnam's rise in manufacturing and technology have made these three countries must-contend spots for all industries going overseas. However, the Southeast Asian region features diverse languages, scattered media forms, and vastly different religious and cultural backgrounds across countries, posing enormous challenges to the PR communication of foreign brands. SeaPRwire's localized expansion this time is precisely to solve this pain point. In Indonesia, SeaPRwire has strengthened cooperation with mainstream Indonesian-language portals in Jakarta and high-traffic social media matrices; in Thailand, the platform seamlessly interfaced with core Thai-language financial and fashion lifestyle media in Bangkok; and in Vietnam, it focused its layout on technology, venture capital, and digital media highly relied upon by the younger generation in Hanoi and Ho Chi Minh City. Through this refined localized media sinking, SeaPRwire ensures that enterprise information can be accurately and losslessly delivered to the most consumable local groups. "To explore the Southeast Asian market, 'groundedness' is the primary factor," stated SeaPRwire's Southeast Asia marketing director. "We are not just translating English drafts into local languages; we are penetrating deep into the media ecosystem capillaries of Indonesia, Thailand, and Vietnam. We hope to use news storytelling that best fits local contexts to help enterprises establish a warm and trusted local brand image." About SeaPRwire SeaPRwire is Asia’s leading AI-driven earned media management platform, purpose-built to empower PR and communications professionals. Through its flagship Branding-Insight Program, the platform connects clients to over 80,000 journalists and an influencer matrix reaching 300 million followers. Leveraging advanced AI, SeaPRwire helps users identify media targets, personalize pitches, and measure PR impact across key APAC markets, including Japan, China, Korea, and Southeast Asia. Media Contact Company: SeaPRwire Contact: Media Relations Team Email: cs@seaprwire.com Website: https://seaprwire.com 04/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 2026-06-04 / 11:06 UTC+8 Hong Kong - 2026年6月3日 - (SeaPRwire) - 东南亚正在成为全球经济增长的新引擎，而印尼、泰国和越南则是其中最耀眼的“活力三驾马车”。为了助力全球企业抢占东南亚市场红利，知名媒体服务商 SeaPRwire 今日宣布，已成功深度打通印度尼西亚、泰国和越南三国的本地主流媒体生态，为出海企业构建了直达东南亚亿级消费者的公关绿色通道。 印尼的人口红利、泰国的消费活力以及越南的制造与科技崛起，让这三个国家成为各行各业出海的必争之地。然而，东南亚地区语言多样、媒体形态分散，且各国的宗教文化背景迥异，这给外来品牌的公关传播带来了极大的挑战。SeaPRwire 此次深入本土的拓展，正是为了解决这一痛点。 在印尼，SeaPRwire 强化了与雅加达主流印尼语门户及高流量社交媒体矩阵的合作；在泰国，平台无缝对接了曼谷核心的泰语财经与时尚生活类媒体；在越南，则重点布局了河内与胡志明市的科技、创投以及年轻一代高度依赖的数字媒体。通过这种精细化的本土媒体下沉，SeaPRwire 确保企业的信息能够准确、无损地传达给当地最具消费力的群体。 “开拓东南亚市场，‘接地气’是第一要素，”SeaPRwire 的东南亚市场总监表示，“我们不仅仅是把英文稿件翻译成当地语言，更是深入到印泰越三国的媒体生态毛细血管中。我们希望用最符合当地语境的新闻叙事，帮助企业建立起有温度、有信任度的本土品牌形象。” 关于SeaPRwire SeaPRwire 是亚洲领先的 AI 驱动型赢取媒体（Earned Media）传播管理平台，专为公关及传播专业人士打造。通过其旗舰项目 Branding-Insight，平台无缝连接超过 8 万名记者、编辑，以及坐拥 3 亿粉丝的 KOL 矩阵。借助先进的 AI 技术，SeaPRwire 帮助用户精准锁定媒体目标、定制个性化推介，并全面衡量亚太核心市场（包括日、韩、中及东南亚）的公关传播效果。 媒体联络 公司: SeaPRwire 联络: Media team 邮箱: cs@seaprwire.com 网站: https://seaprwire.com 2026-06-04 此财经新闻稿由EQS via SeaPRwire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php

EQS via SeaPRwire.com / 03/06/2026 / 16:58 UTC+8 On June 3, 2026, Add New Energy (stock code: 02623.HK), listed on the Main Board of the Hong Kong Stock Exchange, officially renamed as Hong Kong Gold Industry Group Limited, with its short stock name amended to Hong Kong Gold Industry Group (ticker shorthand: HK GOLD IND GP).The name change is far more than a simple rebranding. It marks the culmination of a series of strategic initiatives following the shift in controlling ownership back in October 2025. Unveiling its core development framework on June 1, Hong Kong Gold Industry Group (the “Company”) put forward the "Six Ones" development goals, laying out concrete and quantifiable metrics. The overhaul signals the Company’s full entry into the full value chain of gold, as it embarks on an ambitious journey to build a first-class gold conglomerate in Asia Pacific.   Behind the Rename: Strategy First The planning and rollout of the name change have followed a strategy-first business logic.In October 2025, incoming controlling shareholders Mr. Wu Zhenxing and Ms. Wei Jiaming, alongside veteran investment banker Mr. Wu Haigan, took majority ownership of Add New Energy via HKGG Holdings Limited, securing a combined 55.6% equity stake. This ownership restructure injected new momentum into the listed Company. The new management team restructured the board of directors, assembling an 18-member board comprising industry veterans and sector specialists. In January 2026, the Company kicked off a rights issue offering existing shareholders one new share for every two held at a subscription price of HK$2.88 per share. A total of 175 million new shares were issued, generating net proceeds of approximately HK$503 million, 70% of which is earmarked explicitly for gold resource acquisitions and capital expenditure.Armed with fresh capital, the Company accelerated its global gold asset buildout at a brisk clip. In February 2026, it invested approximately A$39.5 million to subscribe for 36.57 million placement shares in Australian listed gold developer Horizon Minerals Limited (HRZ.AX), equivalent to a 9.95% holding in the developer’s issued capital, marking its entry into gold mining. A month later, the Company upped its strategic bet on the same Australian developer with a A$40.716 million acquisition of another 37.7 million HRZ.AX shares. The Company’s ownership climbed to 19.97%, cementing its position as Horizon’s single largest shareholder. HRZ.AX holds key assets in Kalgoorlie, Western Australia - one of the world’s iconic gold mining hubs. As of February 2026, HRZ.AX boasted total mineral resources of 34.32 million tonnes, translating to roughly 1.88 million troy ounces of contained gold. Its flagship Burbanks asset has substantial upside from further exploration.Concurrently, the Company pushed ahead with its precious metal footprint in China, planning a RMB221 million acquisition of a 20% equity slice in Guixi Baojia Mining via a partnership investment vehicle, granting it exposure to silver mining and processing. Having locked down this roster of tangible assets, the listed entity first announced its proposed name change on April 2, 2026, which received unanimous shareholder approval at an extraordinary general meeting held on April 29. It underscores the Company’s resolute strategic commitment and strong implementation.   Decade-long Blueprint: "Six Ones" Goals and Three-Step Roadmap Released on June 3, the 2026–2035 Ten-Year Strategic Development Outline serves as the Company’s core action guideline for its full transition into gold-focused businesses. Centered on the long-term ambition of building a HK$100 billion gold industrial conglomerate, the document codifies the "Six Ones" goals spanning mining resources, production output, full value chain presence, profitability, market valuation and strategic reserves: Gold mine: To acquire 10 mid-to-large gold mines globally Resource: To build up 1,000 tonnes of proven and probable gold reserves to underpin sustainable long-term growth Production capacity: To hit annual gold output of no less than 10 tonnes, being one of the large- and mid-sized gold producers globally. Profitability: To deliver annual profits of HK$10 billion, building strong and sustainable profitability Capital market: To grow market cap beyond HK$100 billion, maximizing shareholder returns. Asset: To accumulate a 100-tonne gold strategic reserve as a strategic anchor   To deliver on these ambitious goals, the Company has mapped out a robust three-step pathway:Phase 1 - Foundation Building:To secure initial acquisitions of two to three mid-to-large gold mines to add 200–300 tonnes of gold reserves. By 2027, target annual gold output of 2–3 tonnes, HK$2 billion - HK$2.5 billion in annual revenue and a market cap of HK$10 billion - HK$15 billion, cementing its market identity as a specialized gold player.Phase 2 - Rapid Expansion:To expand the global mine portfolio to another six or seven acquired assets, lifting total gold reserves to 600–700 tonnes and elevating the Company into China’s top gold miners. Aspire to annual gold output of 6–8 tonnes, annual turnover ranging from HK$5 billion - HK$6 billion and annual net profit of HK$2 billion - HK$3 billion. This phase will see the buildout of a fully functional overseas operating system with mine production across multiple time zones.Phase 3 - Industry Leadership:To fulfil all metrics under the "Six Ones" goals, achieving 1,000 tonnes of gold resource reserves and annual output above 10 tonnes. Aim to rank among the top 10 gold producers in Asia Pacific with a full value chain ecosystem, and participate in shaping industry standards. Core Competitiveness: Hong Kong’s Geographic Premium + Full Value Chain Buildout As a Hong Kong-based and mainboard-listed company, the Company leverages Hong Kong’s status as both the second largest International financial center and a global gold trading hub to develop differentiated competitive advantages.Hong Kong commands an outsized global share of cross-border gold bullion flows; total cross-border gold flow hit roughly 1,650 tonnes in 2024, accounting for 25% to 27% of all global seaborne gold trade volumes. Capitalizing on this structural edge, the Company plans to launch in-city gold refining operations targeting an incremental gross margin of US$45–US$50 per troy ounce: unlike mainland China’s 13% value-added tax on precious metals, Hong Kong’s zero-tariff regime cuts comprehensive tax costs by US$30–US$40 per ounce, while LBMA-accredited refining certification unlocks an additional US$5–US$8 per ounce premium. Additionally, Hong Kong’s sophisticated cross-border logistics network and dual-currency offshore settlement infrastructure further curtail operating costs and unlock cross-market arbitrage opportunities.From a value-chain perspective, the Company is committed to becoming a fully integrated gold conglomerate spanning upstream mining, midstream metallurgical processing, downstream trading, retail and financial services. Upstream: a targeted global M&A strategy prioritizes high-quality producing or near-production gold mines across China and its neighboring regions, Oceania, Africa and South America, following a tiered asset pipeline approach: holding multiple batches of assets across active producing mines, projects under construction and prospective reserves.Midstream: the Company intends to run Hong Kong-based refining facilities to ride on the Shenzhen Shuibei operating model - "front store plus back factory ", locking in structural cost advantages.Downstream: the Company will expand into gold trading and gold-linked financial services, rolling out gold ETF, options and other derivatives alongside gold leasing and collateralized lending products, plus digital gold solutions (e.g., similar to GoldZip). The Company also plans to set up a mining-focused investment fund targeting upstream mineral opportunities, and build its planned 100-tonne strategic gold reserves as its strategic anchor. Capital Market: Sustainable Valuation Growth Fueled by Global M&As The strategic pivot and renaming are set to drive a fundamental reshaping of the Company’s market valuation. In the gold industry, valuations globally are primarily anchored by proven mineral reserves, operating profit contribution from owned mines and future acquisition scalability. Gold players with production have an average P/E multiple of 12x, versus just 5.7x for near-production miners. The Company intends to lift the share of earnings derived from operational gold mines via sustained reserve acquisitions and capacity ramp-up, which should propel the valuation benchmark materially higher over time.Under its blueprint, the Company targets HK$100 billion in annual operating revenue and HK$10 billion in annual profits by 2035. Applying a forward P/E valuation band of 10x–15x, the implied target market cap ranges between HK$100 billion and HK$150 billion. To realize this valuation milestone, the Company has laid out a clear capital markets roadmap: fund global acquisitions of high-quality gold mineral assets via a mix of equity and bond financing, roll out employee share incentive programs and targeted business spin-offs. It targets lifting its annual dividend payout ratio to 50%–70% by 2030 and sustaining such payout levels on a sustained long-term basis, delivering attractive investment returns to shareholders while clearly communicating the Company’s strategic value to capital markets.The corporate valuations of global top-tier gold producers have consistently leapfrogged via sustained inorganic acquisitions. As illustrated by the Canadian Agnico Eagle, a two-decade string of accretive acquisitions expanded its mineral reserves and delivered substantial outperformance against peer mining stocks. Major Chinese players including Zijin Mining and Chifeng Gold have similarly unlocked robust growth via overseas resource consolidation.   HK Gold Industry Group’s management team boasts an extensive track record in mineral investment and capital markets, with previous exposure spanning multiple Hong Kong-listed gold miners such as Zijin Gold International, Wanguo Gold Group, Chifeng Gold, Lingbao Gold Group, and Zhaojin Mining Industry. With ongoing strategic implementation and steady inflow of high-quality gold assets, the Company is well-positioned to replicate the growth trajectory of established leaders and scale its market cap from HK$10 billion to HK$100 billion.   Closing: Ushering In a New Era for Hong Kong’s Gold Industry The renaming from Add New Energy to Hong Kong Gold Industry Group represents far more than the strategic transformation of a single listed company. It stands as a pivotal milestone for the development of Hong Kong’s broader gold industry.The Company aligns its roadmap with China’s 15th Five-Year Plan and the Hong Kong SAR government’s agenda to cement the city’s position as a global bullion trading hub. The Company has pinned its core development on the value chain of gold, and is committed to emerging as a sector leader to lead the development of Hong Kong’s gold industry. From its refreshed starting point, the Company will leverage Hong Kong’s unique geographic location and international financial center credentials to aggregate global gold mineral resources and build out its full value chain ecosystem. Steady progress against its roadmap and the Six-Ones goals is poised to transform the Company into a first-class gold conglomerate in Asia Pacific over the coming decade, delivering sustainable returns for shareholders. The Company will contribute to Hong Kong’s endeavor to build a globally influential bullion hub, ushering in a new chapter for Hong Kong’s gold industry.   03/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 2026-06-03 / 16:58 UTC+8 6月3日，港交所主板上市公司爱德新能源（02623.HK）正式完成更名，公司全称变更为 “香港黄金产业集团有限公司”，股份简称同步更新为 “香港黄金产业集团”。这一更名绝非简单的品牌焕新，而是公司自去年 10 月控股权变更以来，一系列战略布局的集中落地。与此同时，公司重磅发布未来十年发展战略规划，正式提出 “六个一” 的发展目标，以清晰可量化的指标体系，向资本市场宣告全面进军黄金全产业链赛道，正式开启打造亚太地区一流黄金产业集团的全新征程。 更名背后：战略先行 此次更名的酝酿与落地，始终遵循了战略先行的底层商业逻辑。去年10月，由吴振兴、魏嘉明夫妇通过香港黄金集团控股有限公司（HKGG），联合资深投行专家吴海淦先生共同入主爱德新能源，合计持股比例达55.6%，为公司注入了全新的发展动能。新管理层随即完成董事会改组，组建了由18位资深专家构成的专业董事局，并在今年1月启动供股计划，以每2股配售1股、每股2.88港元的价格发行1.75亿股股份，净募集资金约5.03亿港元，其中70% 明确用于黄金矿业资源的收购与投资。资金到位后，公司以高效的节奏快速推进全球黄金矿业布局。今年2月公司斥资约3950万澳元认购澳大利亚上市公司 Horizon Minerals Limited（HRZ.AX）约3657万股配售股份，占其已发行股本的9.95%，正式切入黄金开采领域。时隔仅一个多月后，公司再度战略加码，以4071.6万澳元收购 HRZ.AX 3770万股股份，持股比例将提升至19.97%，一举成为其第一大股东。HRZ.AX 核心资产位于西澳世界著名金矿带卡古里，截至今年2月，公司拥有矿产资源量3432万吨，合计约188万盎司黄金，旗下Burbanks项目更具备显著的勘探增储潜力。与此同时，公司在国内贵金属资源布局也同步落地，通过合伙企业平台拟以2.21 亿元人民币收购贵溪鲍家矿业20%股权，正式涉足银矿开采与加工。正是在这一系列实质性资产布局落地之后，公司于今年4月2日正式公告发布拟更名公告，并在4月29日的股东特别大会上以100%的赞成票高票通过了更名决议，向市场清晰传递了公司战略转型的坚定决心和强劲执行力。 十年宏图：“六个一”目标与 “三步走”战略 6月3日同步发布的《香港黄金产业集团未来十年发展战略规划纲要（2026-2035）》，是公司全面转型黄金产业的行动总纲领，核心围绕“铸就千亿黄金产业集团” 的宏大愿景，提出了 “六个一” 的发展目标，从资源储备、生产产能、产业链布局、盈利能力、资本市场价值、战略储备六个维度构建了完整清晰的战略目标： 金矿端：全球收购10座大中型金矿； 资源端：保有黄金资源量达到1000吨，奠定长期发展的资源基础； 产能端：实现年产黄金10吨以上，跻身国际大中型黄金生产商行列； 盈利端：实现年利润总额100亿港元，培育强劲且可持续的盈利能力； 资本端：推动市值突破1000亿港元，实现股东价值最大化； 资产端：建立100吨实物黄金战略储备，作为夯实公司战略储备的 “压舱石”。   为了实现上述宏大的战略目标，公司制定了稳健的“三步走”战略：第一阶段基础建设期：完成首批2-3座大中型金矿收购，新增资源量200-300吨；2027年实现黄金产量2-3吨，营收20-25亿港元；支撑市值突破100-150亿港元，树立专业黄金产业集团形象。第二阶段快速扩张期：累计完成6-7座金矿收购，资源量达到600-700吨，跻身国内黄金企业前列；实现黄金产量6-8吨，营收50-60亿港元，年利润20-30亿港元；建立成熟的海外运营体系，形成跨时区生产布局。第三阶段行业领先期：全面达成“六个一”战略目标，黄金资源量达到1000吨，年产量超过10吨；跻身亚太地区前10大黄金生产商行列，深度参与行业标准制定，建成完整的全产业链生态系统。   核心优势：香港区位 + 全产业链布局 作为一家扎根香港的主板上市公司，公司充分利用香港“全球第二大国际金融中心”和“全球黄金交易中心”的双中心独特区位优势，构建起独具特色的差异化核心竞争力。 香港黄金贸易额稳居全球前列，2024年跨境流动总量约1650吨，占全球海运贸易量的25-27%。依托这一优势，公司在香港发展精炼业务，目标可获得每盎司约45-50美元的超额收益：相比内地13%的增值税，香港零关税政策每盎司可节省30-40美元综合税费；LBMA快速通道认证每盎司可产生5-8美元溢价；香港成熟的超级物流网络和离岸双币结算中心，将进一步降低运营成本并创造跨市场套利机会。 在产业链布局上，公司致力于打造集上游开采、中游选炼、下游贸易零售及金融服务为一体的综合性黄金产业集团。上游端，实施精准的全球资源并购策略，重点聚焦中国境内及周边、大洋洲、非洲和南美地区的优质金矿，优先选择在产或投产快的矿山，按照“在产一批、在建一批、储备一批” 的思路梯次配置。中游端，依托香港精炼厂，打造深圳水贝“前店后厂”产业模式，牢牢掌握成本优势。下游端，大力发展黄金贸易和金融服务，开发黄金ETF、期权等多元化金融产品，拓展黄金租赁、抵押等综合金融服务，并推进黄金数字化（如 GoldZip 模式）。同时，公司计划设立矿业投资基金，撬动产业链上游资源，并建立100吨实物黄金战略储备，作为公司的压舱石。   资本市场：全球并购推动市值持续增长 此次战略转型和更名，将推动公司估值体系的全面重塑。黄金行业的核心定价变量是资源量、矿山利润占比和后续并购扩张能力，具备生产能力的黄金企业 PE 平均为12倍，远高于临近投产企业的5.7倍。公司计划通过持续的资源并购和产量释放，逐步提升矿山业务利润占比，推动估值中枢上移。根据规划，公司的目标是到2035年实现营收1000亿港元及年利润总额100亿港元，估值目标为PE 10-15倍，对应目标市值1000-1500亿港元。为实现这一目标，公司制定了明确的资本市场策略：通过股权和债券融资不断在全球并购优质的金矿资源，同时进行股权激励和业务分拆；2030年前将分红率提升至50-70%，并长期维持稳定，为股东创造满意的投资回报，向市场清晰传递公司的战略价值。纵观全球黄金龙头企业的发展历程，持续的外延式并购是实现企业价值跨越式增长的核心路径。加拿大阿格尼克鹰公司（Agnico Eagle）在过去 20 年通过持续并购扩大资源量，股价表现显著跑赢同行；国内的紫金矿业和赤峰黄金也通过海外资源整合打开了成长空间。   香港黄金产业集团核心管理团队拥有深厚的矿业投资背景与丰富的资本运作经验，其过往投资版图覆盖紫金黄金国际、万国黄金集团、赤峰黄金、招金矿业和灵宝黄金等多家港股黄金矿企。随着公司战略转型的深入推进和更多优质黄金资产的落地，有望复制行业龙头的成长路径，实现从十亿到千亿市值的飞跃。   结语：开创香港黄金产业新纪元 从 “爱德新能源” 到 “香港黄金产业集团”，这一名称的变更，不仅是一家上市公司的战略转型，更是香港黄金产业发展史上的重要里程碑。公司积极响应国家“十五五”规划号召和香港特区政府打造“全球黄金交易中心” 的战略部署，将黄金产业链作为战略转型方向，致力于成为引领香港黄金产业发展的领军企业。站在全新的历史起点上，香港黄金产业集团将依托香港的区位优势和国际金融中心地位，整合全球黄金资源，构建完整的全产业链生态系统。随着公司发展战略的稳步落地和 “六个一” 目标的逐步实现，公司有望在未来十年成长为亚太地区一流的综合性黄金产业集团，为全体股东创造持续稳定的回报，同时为香港建设具有全球影响力的黄金交易中心贡献核心力量，共同开创香港黄金产业发展的新纪元。   2026-06-03 此财经新闻稿由EQS via SeaPRwire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php

EQS via SeaPRwire.com / 02/06/2026 / 09:19 MSK Solidcore Resources plc (“Solidcore” or the “Company”) is pleased to announce the appointment of His Excellency (HE) Abdulsalam Al Murshidi, the President of Oman Investment Authority, as a Non-Executive Director and Chair of the Board with effect from 1 June 2026. Omar Bahram will move from the role of Chair of the Board to become Vice-Chair while continuing to serve as a Non-Executive Director. “I am pleased to be nominated for this role and look forward to working closely with management and the Board to support the Company’s development. Solidcore is a key investment in the region for the Sultanate of Oman and my focus will be on strengthening long-term value creation and helping develop and protect our investment through effective governance and strategic oversight”, said Abdulsalam Al Murshidi. “It is a great honor to welcome His Excellency Abdulsalam Al Murshidi as Chair of the Board. His background, strategic perspective, and long-term commitment as the key shareholder representative will be a strong asset as we continue executing our growth strategy and building sustainable value for all stakeholders”, said Vitaly Nesis, CEO of Solidcore Resources plc. The appointment of HE Abdulsalam Al Murshidi was proposed by the Company’s major shareholder Maaden International Investment and approved by the Board. He will stand for election at the upcoming Annual General Meeting of Solidcore, to be held on 24 June 2026 (the “AGM”). The number of Board members will remain unchanged at eight with the majority of the Board remaining independent. Further to this change the new composition of the Board Committees is as follows: The Audit and Risk Committee: Steven Dashevsky (Chair), Evgueni Konovalenko, Richard Sharko. The Remuneration Committee: Richard Sharko (Chair), Janat Berdalina, Evgueni Konovalenko. The Nomination Committee: Evgueni Konovalenko (Chair), Janat Berdalina, Pascale Jeannin Perez. The Safety and Sustainability Committee: Janat Berdalina (Chair), Steven Dashevsky, Pascale Jeannin Perez, Vitaly Nesis. The Investment Committee: Omar Bahram, Steven Dashevsky, Evgueni Konovalenko, Vitaly Nesis. His Excellency Abdulsalam Al Murshidi HE Abdulsalam Al Murshidi currently serves as the President of Oman Investment Authority (OIA), the Sovereign Wealth Fund of the Sultanate of Oman. As part of his duties in OIA, he is the Chairman of the Board of the Gulf Investment Corporation, Kuwait and Governor representing the Sultanate of Oman on the Asian Investment Infrastructure Bank (AIIB) Board of Governors. He is also a member of the Global Commission on Science Missions for Sustainability, International Science Council. He has previously held other positions and founded various industrial, commercial and investment companies in the region. HE Abdulsalam Al Murshidi graduated with distinction from the University of Aberdeen, U.K. with a Master’s Degree of Science in Petroleum Geology (1996). He also holds a Bachelor of Science in Geophysics from the University of Arizona, USA (1989). Current directorships: President of Oman Investment Authority (OIA) (2020 - present); Governor at the Board of Governors of Asian Infrastructure Investment Bank (AIIB) (2020 - present); Chairman of the Board of Directors of Gulf Investment Corporation (GIC) (2026 - present); Member of the Global Commission on Science Missions for Sustainability, International Science Council (2021 - present); Chairman of the Board of Directors of Oman Investment Bank (2024 – present). There is no further information required to be disclosed under Rule 2.6 оf the Market Disclosure Rules Appendix of the AIX Business Rules. About Solidcore Solidcore Resources is a leading gold producer registered in AIFC, Kazakhstan, and listed on Astana International Exchange. Solidcore operates two producing gold mines and a major growth project (Ertis POX) in Kazakhstan. Enquiries Investor Relations Media Kirill Kuznetsov Alina Assanova +7 7172 47 66 55 (Kazakhstan) ir@solidcore-resources.com Yerkin Uderbay +7 7172 47 66 55 (Kazakhstan) media@solidcore-resources.kz FORWARD-LOOKING STATEMENTS   This release may include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements speak only as at the date of this release. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “targets”, “believes”, “expects”, “aims”, “intends”, “will”, “may”, “anticipates”, “would”, “could” or “should” or similar expressions or, in each case their negative or other variations or by discussion of strategies, plans, objectives, goals, future events or intentions. These forward-looking statements all include matters that are not historical facts. By their nature, such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the company’s control that could cause the actual results, performance or achievements of the company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the company’s present and future business strategies and the environment in which the company will operate in the future. Forward-looking statements are not guarantees of future performance. There are many factors that could cause the company’s actual results, performance or achievements to differ materially from those expressed in such forward-looking statements. The company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.   02/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 02/06/2026 / 11:22 UTC+8 From Cell to System. From proven manufacturing experience to localized European support. Not only broad technology coverage, but the operational stability you can depend on. June 9–11, 2026 | Booth 1-B30 European battery manufacturers are moving beyond equipment procurement toward industrial ramp-up, where yield, uptime, process discipline, and local service capability determine long-term competitiveness. As battery manufacturing moves from pilot validation toward industrial-scale production, operational reliability is becoming increasingly critical across the industry.At The Battery Show Europe 2026, Hymson returns for its fifth consecutive year with a clear message for the European market:   “How we make it reliable.” From process validation to mass production. Battery industrialization is not only about installing equipment. It requires process validation, operator training, spare parts readiness, data visibility, and continuous improvement mechanisms. Over the past five years, Hymson has continued to deepen its engagement with the European market, working alongside battery manufacturers amid evolving production demands, technology transitions, and industrial-scaling challenges. This long-term collaboration has enabled Hymson to continuously refine both its technologies and manufacturing methodologies for global battery production environments. Behind this commitment is sustained investment in innovation and engineering capability. By 2025, Hymson’s cumulative R&D investment will reach USD 86 million, with 34.47% of employees dedicated to R&D. Total operating revenue is projected to reach USD 939 million in 2026, supporting continued advancement in next-generation battery manufacturing technologies and industrial delivery capability.   Mid-Section Turnkey Solutions for Scalable Manufacturing At Booth 1-B30, Hymson will present its latest Mid-Section Turnkey Solution through a comprehensive product matrix and a series of scaled technology models showcasing key manufacturing innovations, alongside extensive battery process samples demonstrating end-to-end manufacturing capabilities. The scaled equipment models on display include:  • Solid-State Dry-Electrode Solution • Film-Forming & Calendering & Lamination Integrated Machine  • 390 High-Speed Cutting & Stacking Machine  • CT Inspection Machine for Prismatic Assembly Through these scaled technology models, Hymson will provide visitors with a more intuitive understanding of process integration, equipment architecture, and manufacturing workflow within next-generation battery production environments. Hymson will also showcase: • 588Ah Cell Samples Developed for Overseas Customer Requirements  • 588Ah Cell Cap & Can Laser Welding Samples  • 40+ process samples covering electrode manufacturing, surface treatment, prismatic assembly, and stacking technologies Together, these exhibits reflect Hymson’s integrated approach to mid-section manufacturing — combining process capability, operational consistency, and scalable production performance.   Reliability Starts from Cell Design For Hymson, manufacturing reliability does not begin at equipment installation or even at mass production. It begins much earlier — at the cell design and manufacturability assessment stage. To support customers throughout the entire industrialization journey, Hymson provides an integrated consulting and engineering support framework covering:  • Cell Design to Manufacturing  • Production Line Planning  • Mass Production Line Ramp-up Support  • TrainingA key focus within this framework is manufacturability validation before mass production. For many next-generation battery technologies, laboratory-level performance alone is not sufficient for successful industrialization. To reduce scaling risks, Hymson provides DOE (Design of Experiments) and DTM-based battery process analysis to support parameter optimization, blueprint evaluation, and manufacturability feasibility study. Through this process, Hymson helps customers establish:  • Optimized Process Parameters  • Manufacturable Battery Analysis  • Stable Transition from Validation to Mass Production  • Reduced Ramp-Up Uncertainty and Operational Risks Hymson helps customers translate validated pilot-line conditions into scalable mass-production workflows with thousands of successful delivery and implementation experiences as lessons learned, transitioning into Know-How for the customers, enabling smoother and more accurate alignment between pilot validation and large-scale production environments. This approach helps minimize the risks of industrialization while accelerating mass-production readiness. Technical discussions and in-depth solution exchanges will be available throughout the exhibition.   Digitalized Operations for Long-Term Stability Beyond manufacturing equipment, Hymson will also present its End-to-End intelligent manufacturing support across equipment, logistics, and operations management This includes Hymson’s intelligent warehousing & logistics solution together with the IEMS intelligent equipment operation and maintenance system. Driven by AI algorithms and 3D visual monitoring technologies, the system enables:  • Digital Closed-Loop Production  • Real-Time Operational Visibility  • Intelligent Equipment Maintenance  • Data-Driven Production Management  • Dark-Factory-Oriented Operation Scenarios The system supports higher levels of automation and unmanned operation where applicable by integrating manufacturing execution, logistics coordination, and equipment operation into a unified system, Hymson helps customers improve operational transparency, production efficiency, and long-term factory stability.   Spare Parts Support Built Around Operational Continuity To further strengthen production reliability, Hymson continues to enhance its global spare parts service capability. Hymson provides both original Hymson spare parts and third-party qualified industrial spare parts, tailored to customer requirements, supported by flexible supply mechanisms and predictive inventory planning. The service framework helps customers secure:  • Critical Spare Parts Availability •   Improved Price and Lead-Time Predictability  • Reduced Downtime Risks  Lower Inventory Burden Where Applicable  • Optimized Total Cost of Ownership (TCO) Through data-driven spare parts forecasting and scheduled replenishment systems, Hymson aims to establish a replicable, stable after-sales support structure for long-term manufacturing operations.   Advancing Reliable Battery Manufacturing from Asia to Europe Returning to The Battery Show Europe 2026 for the fifth consecutive year reflects Hymson’s long-term commitment to supporting Europe’s battery manufacturing ecosystem. From process development to intelligent factory operations, Hymson continues to combine large-scale manufacturing experience from Asia with localized industrial collaboration in Europe — helping battery manufacturers build production systems designed not only for technological advancement but also for reliable long-term operation. As Hymson has always stated, visitors are invited to discuss specific challenges such as process validation, ramp-up risk reduction, equipment OEE improvement, spare parts planning, and localized service support.   Company： Hymson Laser Technology Group Co., Ltd. Contact Person:  liruiyu Email: liruiyu@hymson.com Website:  https://www.hymson.com   02/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 2026-05-28 / 09:44 UTC+8 2026年5月26日下午，由全球商报联盟、香港商报联合主办的2026全球商报经济论坛暨「金鲲鹏」中国财经价值榜颁奖盛典，在香港隆重举行。来自香港特区政府、行业协会、上市公司、金融机构等上百位嘉宾出席。 香港商报常务副社长、执行总编辑蓝岸、香港特区政府财经事务及库务局副局长陈浩濂、香港中资证券业协会永远名誉会长谭岳衡等多位领导参会并致辞。 会上公布了2026「金鲲鹏」中国财经价值榜获奖公司。锅圈食品（上海）股份有限公司（2517.HK）（以下简称“锅圈”），一举囊括“最具投资价值上市公司”、“最佳投资者关系管理上市公司”等殊荣。 本次获奖，不仅是对锅圈过去一年资本市场表现的高度认可，更是对其从“万店连锁”向“系统驱动”战略跃迁系列成绩的肯定。 全球商报经济论坛至今已举办八届。本届2026全球商报经济论坛暨「金鲲鹏」中国财经价值榜系列活动以“锚定十五五 抢抓新机遇”为主题，并通过"金鲲鹏"中国财经价值榜旨在遴选引领行业发展变革，业界榜样标杆的杰出企业与人物，以“创新性、公司治理、价值力、战略前瞻性、成长性、社会责任与可持续发展”六大核心维度为评判标准。在组委会和主办机构推荐的基础上，综合入围公司及专业咨询机构提供的客观指标和主观指标两大数据指标计分，经过报名初审、数据采集审定、专家顾问团评审和组委会定榜等环节，最终产生中国财经价值榜企业获奖名单。   全维度创新转化为增长动能，利润增速持续跑赢收入增速 评判一家上市公司的投资价值，最终要回归财务数据的“硬核“验证。在餐饮零售赛道竞争白热化的宏观背景下，锅圈2025年的业绩公告，堪称一份「逆势双增」的珍贵样本。 2025年，公司实现营业收入78.1亿元，同比增长20.7%；核心经营利润4.61亿元，同比增长48.2%；净利润4.54亿元，同比大幅增长88.2%，核心经营利润率提升至5.9%，利润增速约为营收增速的2.3倍；每股基本及摊薄盈利0.163元，同比增长93.8%。与此同时，2025年度股东回报总额5.7亿元，同比增长164.3%。 据锅圈发布2026年度第一季度最新业务情况显示，一季度公司预计收入22-23亿元，同比增长31.3-37.2%；预计实现核心经营利润1.85-2.05亿元，同比增长45.3-61.0%，主要财务指标再次实现增长。 利润增速持续跑赢收入增速，这意味着锅圈已经让增长从“靠速度”走向“靠体系“，源于门店模型优化、供应链降本增效及费用管控的系统性改善，进入规模效应释放与战略升级协同驱动的良性循环，正式迈入高质量增长的新阶段。 门店是锅圈最核心的基础设施。截至2025年末，锅圈全国门店总数达11,566家，全年净增1,416家，扩张节奏持续向好。进入2026年一季度，门店总数进一步增至11,758家，单季净增192家。 公司积极推进在线线下深度融合，通过抖音等社交电商平台的全域布局，2025全年平台曝光量超94.1亿次，门店通过抖音渠道实现GMV达14.9亿元，同比增长75.3%，让在线流量切实转化为单店的经营红利。 与渠道创新相辅相成的，是会员体系的深度运营。锅圈始终将用户资产作为长期增长的核心复利。截至 2025年末，注册会员数量达6490万名，同比增长57.1%；预付卡预存金额达12亿元，同比增长22.3%。 在新业态方面，锅圈小炒的实战落地成为年度创新亮点之一。锅圈小炒作为公司”社区中央厨房“战略重要延伸，不仅丰富了家庭一日三餐的消费场景，更有望成为公司探索第二增长曲线的关键抓手。 同时，公司亦在延伸一站式户外幸福解决方案——锅圈露营。从”家中的餐桌“拓展到”户外社交餐桌“，为消费者提供创造欢乐和情绪价值的全新场景。   发布高比例分红政策，建立稳定的股东回报机制 在资本市场，分红派息是一个受到投资者尤为关注的指标。2025年度，锅圈实现股东回报总额达约5.7亿元，同比增长164.3%，并拟派发2025年末期股息每股0.0381元，总额约1.002亿元。 更为关键的是，锅圈将股东回报从口号转化为制度。2026年4月批准的《股息政策》，每年派息两次（全年业绩及半年业绩获批时宣派），具备条件时优先采用现金分红；2026至2028年度，每年以现金方式分配的利润总额不低于当年归属于公司股东净利润的60%。 这一新的《股息政策》，将为投资者提供了可预期的收益锚点，有利于吸引长期资金投资。 4月22日，锅圈发布公告称，拟投不超2亿港元自有资金回购H股。港交所公告显示，5月22日锅圈以每股2.480港元至2.510港元的价格回购398.20万股，回购金额达994.19万港元。今年以来该股累计进行15次回购，合计回购3413.72万股，累计回购金额9971.73万港元。 这种分红+回购的双轮驱动模式，在港股新消费企业中具有标杆意义。   从“价值传递”到“价值共创”，以透明沟通建立资本市场信任 此次荣获“最佳投资者关系管理上市公司”是对锅圈IR团队专业能力的直接肯定。 回顾锅圈登陆港股后的资本市场沟通轨迹，公司始终保持着高频、透明的信息披露节奏。上市以来，锅圈的IR团队持续扮演好“价值传递者”和“市场倾听者”的双重角色，重视与投资者的多元化、立体化沟通。 除了年度业绩、中期业绩、季报的发布与沟通，IR团队积极组织、参与数百场路演、大型投资论坛、策略峰会。与此同时通过资本市场日、反向路演等形式，带领投资者分析师从一线城市到田间山野，从北方的产业基地到南方的调改门店，实地调研、交流、探讨，帮助资本市场对公司的业务发展有了更直观更深入的全貌理解。过去一年，多家头部券商发布研究报告，对公司持续看好，构建起与机构投资者的高效对话机制。   战略纵深：大店调改开启单店价值全面升维 锅圈将2026年的发展主题锚定为“纵情向前”，这标志着其战略重心发生了深刻转变。公司为今年设定了明确且进取的经营目标：集团门店总数预计突破14,500家，这意味着将净新增超过2,900家门店，同时实现闭店率持续优化。会员总数目标直指9,500万，并推动同店业绩高单位数增长。 实现这一系列目标的核心引擎，在于大店模型的系统性调改与升级。这已成为锅圈2026年最具决定性的战略举措。从第一季度的表现来看，锅圈的增长逻辑已清晰进化——它正逐步摆脱早期单纯依靠拓店数量驱动的外延式扩张，进入一个由门店质量提升、消费场景延伸与运营能力深化共同驱动的全新阶段。这种增长模式更具韧性、更可持续，也意味着公司的价值创造正从“广度”向“深度”迁移。 这种“深度”具体体现在门店角色的根本性重塑上——从过去以销售火锅烧烤食材为主的“货架型”零售点，全面升级为能满足家庭一日多时段、多场景餐饮需求的“社区央厨”和“解决方案中心”。其核心是从“卖产品”转向“经营场景”和“经营用户关系”：通过扩大门店空间、丰富商品组合（如引入早餐、西餐等），并强化热食外摆、明厨亮灶等体验环节，门店不仅提升了顾客的停留意愿与选择广度，更显著增强了承接连带消费和复购的能力。简言之，门店正在变得更“厚”、更“暖”、更能“装下”一个家庭的日常饮食生活。 这一战略转型已初见成效。来自多家机构的调研数据显示，今年以来已完成调改的大店，业绩均获得了显著提升。这证明，通过对存量门店进行“单店革命”，系统性提升其商品力、场景力和运营效率，锅圈正在将其庞大的万店网络，转化为一个价值持续裂变的增长底盘，为未来的高质量增长打开了更具想象力的空间。 第二届金鲲鹏中国财经价值榜给予对锅圈资本市场表现给予认可，不仅是对其过往成绩的肯定，更是对其未来价值的预判。在港股新消费板块估值修复的周期中，一家兼具成长性与股东回报意识的龙头企业，正迎来价值重估的最佳窗口期。 2026-05-28 此财经新闻稿由EQS via SeaPRwire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php

EQS via SeaPRwire.com / 2026-05-27 / 14:20 UTC+8 2026年5月26日，由全球商报联盟、香港商报联合主办的2026全球商报经济论坛暨「金鲲鹏」中国财经价值榜颁奖盛典在香港举行。 会上公布了2026「金鲲鹏」中国财经价值榜获奖公司及企业家名单。环球新材国际控股有限公司（股票代码：06616.HK）一举斩获“十五五最具投资价值上市公司”奖项，公司董事局主席、行政总裁苏尔田博士同步获评“最具影响力上市公司董事长”。 金鲲鹏奖由中国财经价值榜经由严格的企业价值评估与行业影响力评选产生，获奖企业需在产品力、盈利能力、成长性与社会价值等多个维度上达到行业标杆水准，颁奖典礼汇聚了来自香港特区政府、行业协会及金融机构的数百位嘉宾。 本次获奖名单中，环球新材国际是新材料细分领域唯一同时斩获两项大奖的企业。这不仅是一次行业荣誉的加冕，更是国际资本市场对环球新材国际在全球化洗牌期中，通过高阶产业并购实现“全球化平台型企业”战略跨越的积极投票。 对于成熟的机构资金而言，若仅以传统的静态市盈率去评估一家正处于深度整合期的大型产业并购企业，容易忽略整合初期的非现金支出与阶段性投入。穿透利润表的技术性波动，关注企业的真实造血能力、内生增长弹性以及集团全年营收增速的可见度，往往是国际资本对这类公司进行中长期价值判断的底层逻辑。本次环球新材国际获评“十五五最具投资价值上市公司”，一定程度上也反映了市场对其并购整合逻辑与成长能见度的认可。   锚定“十五五”战略规划，破局行业卡脖子瓶颈，尽显领跑龙头优势 新材料产业作为国家“十五五”规划重点培育和优先发展的新兴支柱产业，是支撑高端制造和科技创新的核心基石，更是我国关键领域在国际博弈中免受海外“卡脖子”制约的战略底座。 环球新材国际作为国家工信部工业强基工程人工合成云母项目的核心承担单位，其核心产品人工合成云母已被精准列入《产业结构调整指导目录（2024年本）》鼓励类产业范畴。这种国家层面的战略卡位，不仅为公司赢得了重资产、高壁垒工业新材料赛道的硬核政策红利，更赋予其作为行业标杆引领中国表面性能材料行业不断进阶发展的时代使命。 这种承接国家战略的硬核实力，并没有停留在顶层设计蓝图上，而是在环球新材国际密集落地的重大产业项目中，得到了价值兑现。 2026年2月，设计年产能10万吨的桐庐人工合成云母项目顺利点火投产，不仅标志着目前全球规模最大、技术领先的合成云母生产基地正式进入商业化运营期，更在产业安全层面，强化我国新材料垂直产业链的自主可控。 作为国家关键基础新材料之一，人工合成云母是先进制造业体系的重要组成部分。环球新材国际桐庐项目专注于高品质人工合成云母及其延伸产品的研发与产业化，将为公司全球供应链提供稳定的高品质合成云母核心基材，有效解决天然云母采购成本高、ESG采购溢价等痛点，从原材料端强化自主供给能力。 弗若斯特沙利文数据显示，全球珠光材料市场规模预计到2030年将突破500亿元，其中中国市场有望斩获135亿元的庞大体量，整个赛道正处于需求引爆的黄金节点。特别是在新能源汽车崛起与高端车漆美学迭代的双重驱动下，汽车领域的珠光材料需求正呈现出爆发式增长，而这恰恰是过去国产材料最难攻克的壁垒。 由战略背书到产能破局、再到布局高附加值市场的逻辑闭环已然形成，环球新材国际得以在全球表面性能材料行业，加速向科技平台型龙头集中的洗牌期中，实现从“跟随者”到“引领者”的跨越。   跨国外延并购释放协同红利，致力打造全球化表面性能材料平台型企业 一家企业能走多远，往往取决于其掌舵人的战略远见与思想厚度。荣获“最具影响力上市公司董事长”荣誉的苏尔田博士，其战略思想始终强调“以内生研发筑底、借外延并购破局”的发展观。 苏尔田博士致力于将公司打造为一家全球化表面性能材料平台型企业。正是基于这种具有前瞻性的资本与产业视野，公司在2025年成功完成了对默克集团表面解决方案业务苏索（SUSONITY）100%股权的战略并购与交割。 在从中国龙头走向全球平台这一跃迁过程中，环球新材国际基于“引进来走出去”的全球化双循环出海理念，已构建起可持续的双向价值转化路径。 外延破局上，环球新材国际依托此前对德国默克集团表面解决方案业务苏索（SUSONITY）及韩国CQV的跨国并购整合，全面导入服务全球顶级汽车、化妆品等高端应用领域60余年的成熟技术体系与全球化渠道网络，打通欧美核心市场通路。2025年，公司在欧洲地区销售额同比激增555.0%，北美洲销售额同比大增1,047.5%，海外市场的营收贡献空间正在加速打开。 内生筑底上，环球新材国际将具备国际顶尖技术能力的高端产品线对接中国及亚太消费市场。近期，公司旗下SUSONITY与中国驱蚊行业领军品牌润本正式签署战略合作协议，双方围绕驱蚊产品研发、技术创新与市场拓展展开深度合作，推动国际领先的技术体系与中国成熟消费品牌实现产品级的价值共振。目前环球新材国际已在全球布局六大研发中心、六大应用中心及六大制造中心，销售网络覆盖全球150余个国家和地区，旗下三品牌——七色珠光、SUSONITY、CQV已形成从研发、生产到区域应用的全链路协同矩阵。 在评价一场跨国并购的成败时，海外子公司的内生造血能力是最硬核的试金石。CQV在2026年一季度业绩“深蹲起跳”，释放全年高增速可见度，其核心业务收入及销量均实现同比强劲增长。其中，氧化铝基及玻璃基等高附加值产品销量大幅扩大，并加速从韩国本土向全球海外市场渗透。 比亮眼数据更具说服力的，是管理层在二级市场的“真金白银”增持。在2026年4月连续增持近244.2万股普通股后 ，苏尔田主席于5月13日及14日再度密集出手，分别增持77.3万股和23.2万股。这种在短时间内高频、大笔的现金增持，彰显管理层对公司长期造血韧性的坚定信心。   多元化产品谱系：5000+效果颜料构筑护城河，活性物第二曲线破局高增长 在产品叙事上，环球新材国际已彻底摆脱了单一材料企业的周期性风险，呈现出现金流业务极度稳固、成长性业务边界大开的多元化矩阵。 超5000款效果颜料矩阵，是环球新材国际稳固的基本盘。公司始终践行全球整合与自主研发的战略，构筑起多基材、全场景的产品谱系，进而在利润丰厚的高端汽车、数码电子、工业涂料、化妆品等领域建立起极高的客户粘性与竞争壁垒。2025年环球新材国际的珠光效果颜料收入录得25.3亿元，同比大幅增长65.8%，为公司持续扩张提供了扎实、抗周期的自由现金流保障，夯实了底层造血基础。 稳定基本盘的同时，环球新材国际通过并购SUSONITY，顺理成章地将高端化妆品活性物（Active Ingredients）业务纳入麾下，使其成为集团切入大健康与高端美妆赛道的重要战略布局。作为原默克表面解决方案体系中的核心产品系列，活性物业务具备极高的技术壁垒、极佳的毛利表现以及高频的客户复购特征。依托该国际顶尖资产，环球新材国际利用尖端的无机包裹技术与表面改性工艺，提供具备优异皮肤屏障修护、抗光老化、安全防晒等核心功能的高端化妆品活性成分。 环球新材国际第二增长曲线的打造，精准顺应了全球纯净美妆与科学护肤的时代浪潮，有效打破了海外特种化学品巨头在高端活性物领域的垄断。这种由高附加值效果颜料向大健康活性物领域的纵深跨越，不仅量质并举地拓宽了技术边界，更在商业变现层面为公司打开了全新的盈利增长空间。 面向“十五五”产业新格局，环球新材国际依托技术壁垒、全球产能布局与产业链整合能力，中长期成长动力持续显现。 长江证券近期研报指出，公司中端市场凭借规模及合成云母优势，叠加产能扩张，份额有望进一步提升；通过SUSONITY、CQV的渠道与技术资源，高端市场拓展路径清晰；协同降本效应值得期待。环球新材国际收购韩国CQV及默克表面解决方案业务后，渠道协同、产品导入、成本优化与技术互补有望形成“1+1+1>3”的整合效果，故维持“买入”评级。 2026-05-27 此财经新闻稿由EQS via SeaPRwire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php